Development of Accurate Long-lead COVID-19 Forecast

Wan Yang[1,2] and Jeffrey Shaman[3,4]

[1]Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; [2]Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA; [3]Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA; [4]Columbia Climate School, Columbia University, New York, NY, USA

Correspondence to: wy2202@cumc.columbia.edu (WY)

Short title: Long-lead COVID-19 forecast

One sentence summary: To support more proactive planning, we develop COVID-19 forecast methods that substantially improve accuracy with lead time up to 6 months.

Abstract

Coronavirus disease 2019 (COVID-19) will likely remain a major public health burden; accurate forecast of COVID-19 epidemic outcomes several months into the future is needed to support more proactive planning. Here, we propose strategies to address three major forecast challenges, i.e., error growth, the emergence of new variants, and infection seasonality. Using these strategies in combination we generate retrospective predictions of COVID-19 cases and deaths 6 months in the future for 10 representative US states. Tallied over >25,000 retrospective predictions through September 2022, the forecast approach using all three strategies consistently outperformed a baseline forecast approach without these strategies across different variant waves and locations, for all forecast targets. Overall, probabilistic forecast accuracy improved by 64% and 38% and point prediction accuracy by 133% and 87% for cases and deaths, respectively. Real-time 6-month lead predictions made in early October 2022 suggested large attack rates in most states but a lower burden of deaths than previous waves during October 2022 – March 2023; these predictions are in general accurate compared to reported data. The superior skill of the forecast methods developed here demonstrate means for generating more accurate long-lead forecast of COVID-19 and possibly other infectious diseases.

Author Summary

Infectious disease forecast aims to reliably predict the most likely future outcomes during an epidemic. To date, reliable COVID-19 forecast remains elusive and is needed to support more proactive planning. Here, we pinpoint the major challenges facing COVID-19 forecast and propose three strategies. Comprehensive testing shows the forecast approach using all three strategies consistently outperforms a baseline approach without these strategies across

39 different variant waves and locations in the United States for all forecast targets, improving the
40 probabilistic forecast accuracy by ~50% and point prediction accuracy by ~100%. The superior
41 skills of the forecast methods developed here demonstrate means for generating more
42 accurate long-lead COVID-19 forecasts. The methods may be also applicable to other infectious
43 diseases.
44
45 **Keywords:** COVID-19 forecast; long lead-time; error growth; new variants; infection seasonality
46
Main text
INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019,
causing the coronavirus disease 2019 (COVID-19) pandemic. Since its onset, mathematical
modeling has been widely applied to generate projections of potential pandemic trajectories,
including for cases, hospitalizations, and deaths. These model projections are often based on
specific assumptions (i.e., scenarios) regarding critical factors affecting transmission dynamics.
For example, the scenarios often include a combination of public health policies [e.g., non-
pharmaceutical interventions (NPIs) including lockdown/reopening and masking, and
vaccinations], population behavior (e.g., adherence to the policies and voluntary preventive
measures), and anticipated changes in the epidemiological properties of SARS-CoV-2 variants
(1-4). While such efforts have provided overviews of the potential outcomes under various
scenarios, they do not assign likelihoods to the scenarios/projected trajectories, and the most
likely trajectory is typically not known until the outcome is observed. That is, scenario
projection is not equivalent to calibrated infectious disease *forecast*, which aims to reliably
predict the most likely future outcomes during an epidemic. As COVID-19 will likely remain a
major public health burden in the years to come, sensible forecast of the health outcomes
several months in the future is needed to support more proactive planning.
65
Compared to forecast of epidemic infections (e.g., influenza), a number of additional challenges
exist for long-lead COVID-19 forecast. First, SARS-CoV-2 new variants will likely continue to
emerge and remain a major source of uncertainty when generating COVID-19 forecasts (5, 6).
As has been observed for the major variants of concern (VOCs) reported to date (i.e., Alpha,
Beta, Gamma, Delta, and Omicron), future new variants could arise at any time, could quickly
displace other circulating variants, and could be more contagious than pre-existing variants,
and/or erode prior infection- and/or vaccination-induced immunity to affect underlying
population susceptibility. Further, multiple new variants could arise successively to cause
multiple waves during a time span of, e.g., 6 months. Such frequent emergence and fast
turnover of circulating variants is in stark contrast with epidemic infections. Second, many
infections for other respiratory viruses tend to occur during a certain season of the year and as

such, the seasonality can be incorporated to improve forecast accuracy (7, 8) as well as restrict
the forecast window to the epidemic season (e.g., influenza during the winter in temperate
regions). Potential seasonality for SARS-CoV-2 is still not well characterized. For instance, in the
US, where larger waves have occurred in the winter during 2020-2022, smaller summer waves
have also occurred (e.g. the initial Delta wave and Omicron subvariant waves; Fig 1). Third,
given the unknown timing of new variant emergence, year-round, long-lead COVID-19 forecast
will likely be needed. These unknowns also necessitate wider parameter ranges using a forecast
ensemble to account for the uncertainty, which over long forecast horizons could lead to
greater error growth and poorer predictive accuracy.
86
In this study, we aim to address the above challenges and develop sensible approaches that
support long-lead prediction of COVID-19 epidemic outcomes. We propose three strategies for
improving forecast accuracy and test the methods in combination by generating retrospective
forecasts of COVID-19 cases and deaths in 10 representative states in the US (i.e., California,
Florida, Iowa, Massachusetts, Michigan, New York, Pennsylvania, Texas, Washington, and
Wyoming; Fig 1). Relative to a baseline approach, the forecast approach based on our
strategies largely improves forecast accuracy (64%/38% higher probabilistic log score for
cases/deaths, and 133%/87% higher point prediction accuracy for cases/deaths, tallied over
25,183 evaluations of forecasts initiated during July 2020 – September 2022, i.e., from the end
of the initial wave to the time of this study). These results highlight strategies for developing
and operationalizing long-lead COVID-19 forecasts with greater demonstrated accuracy and
reliability. In addition, we generate real-time COVID-19 forecasts for October 2022 – March
2023 (roughly covering the 2022-2023 respiratory virus season) and evaluate these forecasts
using data reported 6 months later.
101
RESULTS
Proposed strategies for long-lead COVID-19 forecast
To address the three challenges noted above, we propose three strategies in combination.
Details are provided in Methods. Here, we summarize the idea behind each strategy. The first
strategy is to constrain error growth during the extended forecast period. As noted above, the
multiple uncertainties regarding SARS-CoV-2 (e.g., new variant properties) necessitate wider
distributions of the state variables (e.g., population susceptibility) and parameters (e.g., virus
transmissibility) at the point of forecast initiation. With a wider forecast ensemble, some
ensemble members could predict earlier, large outbreaks, which if premature, would deplete
modeled susceptibility and incorrectly preclude outbreaks later on. More generally, like other
infections, COVID-19 epidemics often grow exponentially at first, triggering exponential
changes in susceptibility and other state variables, which in turn feed back on the longer
epidemic trajectory. Such infectious disease dynamics imply forecast error can also grow

exponentially, leading to accelerated degradation of forecast accuracy after the first few weeks.
To counteract this exponential error growth, we propose to apply a multiplicative factor γ <1 to
the covariance of the forecast state variables (e.g., susceptibility) while retaining the ensemble
mean (see Methods). In so doing, we can represent initial uncertainty with a broad forecast
ensemble while countering excessive error growth of the state variables. This strategy is similar
to covariance inflation during system optimization (9, 10), where a γ >1 is applied to the
covariance to counteract over-narrowing of the model ensemble. Since here it acts in the
opposite direction, we refer to this technique as deflation. Fig 2A shows example forecasts
with deflation compared to without it.
124
The second strategy is to anticipate the impact of new variants. Genomic sequencing data can
support prediction of the impact of a new variant a few weeks in the future (see Methods and
the SI); however, variant displacement and competition dynamics can occur unexpectedly
beyond those first few weeks, rendering historical data less relevant. Thus, for weeks farther in
the future, instead of predicting specific new variants, we propose to use a set of heuristic rules
to anticipate their likely emergence timing and impact on population susceptibility and virus
transmissibility. Specifically, for the timing, we reason that new variants are more likely to
emerge/circulate 1) after a large local wave when more infections could lead to more
mutations, which could be timed based on local outbreak intensity during the preceding
months; and 2) during a time when a large part of the world is experiencing a large wave, which
also could lead to new mutations. For instance, in the US, this could be during the winter when
local large waves tend to occur, or the summer when places in the southern hemisphere are
amid their winter waves. As such, this could be timed based on the calendar. For the new
variant impact, we observe that, new variant circulation often results in gradual increases in
susceptibility (e.g., a few percentages per week, based on estimates from New York City during
VOC waves), possibly due to the substantial population immunity accumulated via infections
and vaccinations. Similarly, changes in transmissibility also tend to occur gradually. As such, we
propose to apply small increases to the model population susceptibility and transmissibility
during those two plausible times. The rationale here is to anticipate the more common, non-
major changes so as not to overpredict, because major VOCs causing dramatic changes are
rarer and difficult to predict. Fig 2B shows example forecasts with these new variant settings
compared to without them.
147
The third strategy accounts for seasonality. Instead of assuming a specific epidemic timing, we
model the seasonal risk of SARS-CoV-2 infection based on plausible underlying drivers of
infection seasonality for common respiratory viruses. Specifically, studies have shown that
respiratory viruses including SARS-CoV-2 are sensitive to ambient humidity and temperature
conditions, which could in turn modulate their survival and transmission (11-15). Accordingly,

we developed a climate-forced model that includes both humidity and temperature to capture
the reported virus response and parameterized the model based on long-term epidemic data
observed for influenza (16). When modified and applied to account for SARS-CoV-2 seasonality
in a model-inference framework, the estimated seasonal trends are able to capture the effects
of different climate conditions (e.g., for UK, Brazil, India, and South Africa (17-19)). Here, we
thus propose to apply this model and local climate data to estimate SARS-CoV-2 seasonality in
each location (referred to as "fixed seasonality"; see estimates for the 10 states in Fig S1). In
addition, as the model is parameterized based on influenza data, this estimated seasonality
could differ from the true SARS-CoV-2 seasonality. To test this, we propose an alternative
seasonality form that transforms the fixed seasonality trend to allow a more flexible phase
timing and structure of seasonality (referred to as "transformed seasonality"; see details in the
SI and examples for the 10 states in Fig S1). Fig 2C shows a comparison of the two seasonality
forms and example forecasts with no seasonality and the two seasonality forms.
166
We test the above three strategies in combination, including three deflation settings (i.e.,
setting γ = 1, 0.95, and 0.9), two new variant settings (i.e., assuming no new variants vs.
anticipating new variants per the rules noted above), and three seasonality settings (i.e., no,
fixed, and transformed seasonality): in total, 12 (= 3 × 2 × 3) forecast approaches. To compare
the performance of the 12 forecast approaches, we generated retrospective forecasts for 10
states, from July 2020 – August 2021 (Pre-Omicron period; 65 weeks in total) and December
2021 – September 2022 (Omicron period; ~37 weeks). For each week, a forecast for the
following 26 weeks (~6 months) is generated after model training using data up to the week of
forecast. We then evaluate the accuracy predicting the weekly number of cases and deaths
during each of the 26 weeks (i.e. 1- to 26-week ahead prediction), as well as the peak timing
(i.e. the week with the highest cases/deaths), peak intensity, cumulative number of cases and
deaths over the 26 weeks.
179
For the forecast comparisons below, we evaluated probabilistic forecast accuracy using log
score, i.e., the logarithm of the probability correctly assigned to the true target (see Methods
and SI). We also evaluated point prediction accuracy – assigning value 1 (i.e., accurate) to a
forecast if the point prediction is within ±25% of the observed case/death count or within ±1
week of the observed peak week, and 0 (i.e., inaccurate) otherwise; as such, when averaged
over all forecasts, this accuracy gives the percentage of forecasts a point prediction is accurate
within these tolerances. Thus, both higher log score and higher point prediction accuracy
indicate superior forecast performance.
188
The impact of deflation

Compared to forecasts with no deflation ($\gamma = 1$), applying a small deflation ($\gamma = 0.95$ or 0.9)
consistently improves forecast performance (Fig 3, first two panels). This improvement is
evident across all locations and combinations of the other two model settings (i.e., new variants
and seasonality). The improvement is most pronounced for the long-lead (i.e., 17- to 26-week
ahead) weekly forecasts and overall intensity-related targets (i.e., the totals accumulated over
26 forecast weeks and peak intensity; Figs S2-3), indicating deflation is able to effectively
reduce error growth accumulated over time. We note that, as deflation works by reducing
forecast spread, the forecast ensemble can also become under-dispersed, assign zero
probability to the true target (most notably, for peak week), and in turn produce a lower log
score (see Fig S2, the 3rd row of each heatmap for peak week). Given this trade-off, we did not
test deflation factors <0.9.
201
Overall, relative to forecasts without deflation ($\gamma = 1$), log scores aggregated over all locations
and targets were 18 – 20% higher for forecasts of cases (range of relative change across all
combinations of the other two model settings; Table S1) and 7 – 8% higher for forecasts of
mortality when a deflation factor γ of 0.95 was applied. The log scores further increased when
using $\gamma = 0.9$, to 34 – 43% higher (than $\gamma = 1$) for forecasts of cases and 13 – 17% higher for
forecasts of mortality. The improvement of point prediction accuracy was more pronounced.
Aggregated over all locations and targets, point prediction accuracy was 33 – 63% higher for
forecasts of cases and 24 – 40% higher for forecasts of mortality when using a deflation factor γ
of 0.9, relative to using no deflation (Table S1). As such, we use $\gamma = 0.9$ as the best-performing
setting for subsequent analyses.
212

Impact of the new variant settings
To ensure consistency and avoid over-fitting, we applied the same set of heuristic rules on new
variant emergence timing and impact, as noted above, throughout the entire study period (i.e.,
including weeks before the emergence of SARS-CoV-2 VOCs). We expect the new variant
settings to improve forecast performance during VOC waves but have a less pronounced or no
effect during the 2nd wave (roughly, fall/winter 2020 – 2021), prior to VOC emergence. Indeed,
overall, for the 2nd wave, forecast systems with the new variant settings (referred to as "new
variant model") had similar performance as those assuming no new variants (relative changes
in log score and accuracy: -2% to 0.6%, Table S2; Fig 4). However, for the VOC waves, applying
the new variant settings improved forecast performance during the Alpha wave (roughly, spring
2021), Delta wave (roughly, summer/fall 2021), and Omicron wave (after December 2021; note
no further desegregation was made for Omicron subvariant waves due to small sample sizes;
Fig 4). For forecasts of cases, the improvement was consistently seen for all three VOC waves
(relative changes in log score and accuracy all > 0, Table S2). The relative increases of log score
were up to 119% during the Delta wave and up to 37% during the Omicron wave; the relative

increases of point prediction accuracies were up to 89% during the Delta wave and up to 96%
during the Omicron wave (Table S2 and Fig 4).
230
For forecasts of mortality, the new variant model had higher log scores during the Alpha and
Delta waves, as well as higher point prediction accuracies during all three VOC waves (Table S2).
However, log scores during the Omicron wave were similar for both models (e.g., overall log
scores: -0.22 for the new variant model and -0.17 for the baseline, both assuming no
seasonality); in addition, the log scores were slightly lower for the new variant model, likely due
to the lower COVID-19-associated deaths during the Omicron wave.
237
238 Aggregated over all waves, targets, and locations, the new variant model had 17 – 34% and 3 –
239 8% higher log scores and 23 – 28% and 22 – 25% higher point prediction accuracies for
240 forecasts of cases and deaths, respectively.
241
Impact of seasonality forms
Based on the above results, we focus on forecasts generated using the new variant model with
a deflation factor of 0.9 to examine the three approaches to forecasting the effects of
seasonality. As noted above, seasonality aims to capture changes in infection risk in response to
environmental conditions (here, ambient humidity and temperature); for common respiratory
viruses (e.g., influenza), infection risk in temperate regions is often higher during cold-dry
winter months (i.e., respiratory virus season, roughly mid-October to mid-April in the US), and
lower during the rest of the year (i.e., off season). Both the fixed and transformed seasonality
models consistently improved forecast performance during the respiratory virus season relative
to the no seasonality approach across all locations and targets (Fig 5A for log score and 5B for
point prediction accuracy, first two panels; Table S3). However, if only analyzing the off season,
both models had worse performance compared to the model assuming no seasonality (Fig 5, 4th
and 5th panels). Segregating the forecasts made for the off season by wave shows that both
seasonality models continued to outperform the no seasonality model during summer/fall 2020
(grouped with the 2nd wave); worse performance occurred during summer/fall 2021 (the Alpha
and Delta waves) and summer 2022 (Omicron subvariants; Table S3). These results suggest that
the seasonality models are able to capture the seasonal risk of SARS-CoV-2 infection, and that
the degraded performance during the off season may be due to challenges anticipating the
initial surge of VOCs occurring during those times.
261
Tallied over all time periods, in general, the seasonality models outperformed the no
seasonality model (Table S3 for all locations combined and Table S4 for each location).
Comparing the two seasonality forms, the transformed seasonality model outperformed the
fixed seasonality model overall (Table S3). Compared to the no seasonality model, the

transformed seasonality had 14% higher log score for forecasts of mortality, and 26% and 18%
higher point prediction accuracies for cases and mortality, respectively (Table S3). As noted
above, the improvement during the respiratory virus season was more substantial (Tables S3
and S4; Fig 5).
270
Combined impact of deflation, new variant settings, and seasonality forms
We now examine the forecast performance using the combined best-performing approach (i.e.,
applying deflation with γ = 0.9, the new variant rules, and the transformed seasonality form),
compared to the baseline approach (i.e., no deflation, no new variants, and no seasonality). In
addition to the large uncertainties surrounding SARS-CoV-2 (e.g., new variants), there are also
large spatial heterogeneities. For example, across the 10 states included here, population
density ranged from 6 people per square mile in Wyoming to 884 per square mile in
Massachusetts (2020 data (20)); climate conditions span temperate (e.g., New York) and
subtropical climates (e.g., Florida; Fig S1). Given the uncertainties and spatial heterogeneities,
the robustness of any forecast approach is particularly important.
281
First, we examine the consistency of forecast performance over different variant periods.
During the pre-Omicron period (here, July 2020 – Dec 2021), the combined approach
consistently outperformed the baseline approach across all states, for both forecasts of cases
and deaths (Fig 6A); log scores improved by 85% overall for cases (range from 39% in
Washington to 134% in Florida) and by 62% overall for deaths (range from 24% in Washington
to 117% in Florida; Table 1). During the Omicron period (here, Dec 2021 – September 2022),
improvements were smaller but consistent across the 10 states for forecast of cases (Fig 6A;
note that only 16-20 forecasts of long-lead targets were evaluated here, as observations are
incomplete); as noted above, due to the much lower mortality during the Omicron period, both
the best-performing and baseline forecasts of mortality had similar log scores (e.g., median
difference = -0.02, Table 1). The overall consistency of the performance indicates that the best-
performing forecast approach is robust for forecasting long-lead COVID-19 epidemic outcomes
for different variants.
295
Second, we examine the forecast performance during the US respiratory virus season (here,
mid-October to mid-April) when larger COVID-19 waves have occurred. Tallied over all weeks
during the respiratory virus season, the best-performing approach outperformed the baseline
approach for all 10 states (Fig 6B); log scores increased by 105% for cases (range from 32% in
Washington to 213% in Massachusetts) and by 85% for mortality (range from 19% in
Washington to 158% in Iowa; Table 1). During the off season, the best-performing approach
also generally outperformed the baseline approach (Table 1).
303

Third, we examine the accuracy predicting different epidemic targets. The best-performing
forecast approach consistently improved point prediction accuracy for all targets for all 10
states (Fig 7 and Table 2). In addition, the improvement was more substantial for long-lead
targets (e.g., 9- to 16-week ahead and 17- to 26-week ahead forecasts, peak week, peak
intensity, and the cumulative totals). For instance, the best-performing approach increased
accuracy from 24% to 42% (35% to 56%) predicting the peak week of cases (deaths), from 20%
to 40% (30% to 50%) predicting the peak intensity of cases (deaths), roughly a 2-fold
improvement for these two long-lead targets. The improvements were even more substantial
for 17-26 week ahead forecasts and the cumulative totals over the entire 26 weeks (by 3- to 22-
fold, Fig 7 and Table 2). We note the forecasts here were generated retrospectively with
information that may not be available in real time and thus likely are more accurate as a result.
Nonetheless, with the same information provided to both forecast approaches, the comparison
here demonstrates the large improvement in forecast accuracy using the best-performing
forecast approach.
318

Forecast performance compared with ARIMAX models
To benchmark the performance of the forecast approaches developed here, we also generated
retrospective forecasts using Auto-Regressive Integrated Moving Average (ARIMA) models.
Compared to the best-performing ARIMAX model (identified from 5 models with different
settings; see Methods and Table S5), our baseline approach (i.e., no deflation, no new variants,
and no seasonality) performed similarly well whereas our best-performing approach (i.e.,
applying deflation with $\gamma = 0.9$, the new variant rules, and the transformed seasonality form)
had much superior performance (Table S6).
327

Forecast for the 2022 – 2023 respiratory virus season
Figs 8-9 present real-time forecasts of October 2022 – March 2023 for the 10 states, and Table
S7 shows a preliminary accuracy assessment based on data obtained on March 31, 2023.
Accounting for under-detection, large numbers of infections (i.e., including undocumented
asymptomatic or mild infections) were predicted in the coming months for most states;
predicted attack rates over the 6-month prediction period ranged from 16% (IQR: 7 – 31%) in
Florida to 30% (IQR: 15 – 47%) in Massachusetts (Fig 9). Relatively low case numbers and fewer
deaths at levels similar to or lower than previous waves were forecast, assuming case
ascertainment rates and infection-fatality risks similar to preceding weeks (Fig 9). Compared to
data reported 6 months later (i.e., not used in the forecasts), the weekly forecasts in general
captured trajectories of reported weekly cases over the 6 months for all 10 states (Fig 8, middle
column for each state) but under-predicted deaths for half of the states (i.e., New York,
Massachusetts, Michigan, Wyoming, and Florida; Fig 8, right column for each state). For the
cumulative totals, predicted IQRs covered reported tallies in all 10 states for cases and the

majority of states for deaths, while the 95% predicted intervals covered reported cumulative
cases and deaths in all states (Fig 9).
344
DISCUSSION
Given the uncertainties surrounding future SARS-CoV-2 transmission dynamics, it is immensely
challenging to accurately predict long-lead COVID-19 epidemic outcomes. Here, we have
proposed three strategies for sensibly improving long-lead COVID-19 forecast. Retrospective
forecast accuracy is substantially improved using the three strategies in combination during
both the pre-Omicron and Omicron periods, including for long-lead targets 6 months in the
future. This improvement is consistent among 10 representative states across the US, indicating
the robustness of the forecast method.
353
Our first strategy addresses the accumulation of forecast error over time. The simple deflation
method proposed here substantially improves forecast accuracy across different model settings
(here, different new variant and seasonality forms), time periods (pre-Omicron vs Omicron),
and locations (different states). This consistent improvement indicates that deflation is
effective in constraining outlier ensemble trajectories. Albeit possibly a severer issue for SARS-
CoV-2 due to larger uncertainties and less constrained parameter estimates, error growth is a
common challenge in forecasts of infectious diseases not limited to COVID-19 (21, 22). Future
work could examine the utility of deflation in improving forecast accuracy for other infectious
diseases.
363
Another challenge facing COVID-19 forecast derives from the uncertainty associated with new
variant emergence. Based on past epidemiological dynamics of and population response to
SARS-CoV-2 VOCs, we proposed a simple set of heuristic rules and applied them universally
across time periods and locations. Despite their simplicity, the results here show that these
heuristics substantially improved forecast accuracy compared to forecasts generated without
them. These findings suggest that, while it is challenging to forecast the emergence of specific
variants, the timing of future variant emergence and the impacts on key epidemiological
characteristics (i.e., population susceptibility and virus transmissibility) can be learned from
past VOC waves and used to support more accurate forecast. Much uncertainty remains
regarding future SARS-CoV-2 genomic evolution and population immunity; however, the
heuristics proposed here represent a first step anticipating the dynamic interplay of SARS-CoV-2
new variants and population immunity. Continued work to test the robustness of these
heuristics as SARS-CoV-2 and population immunity continue to co-evolve is thus warranted.
377
The third focus of this study is seasonality. Several prior studies have examined the potential
seasonality of COVID-19, using methods such as time series analyses, regression models, and

sinusoidal functions (23-25). However, the underlying mechanisms and likely nonlinear
response to seasonal drivers are not fully characterized. Several concurrent changes including
case ascertainment rate, NPIs and voluntary behavioral changes, and new variants further
complicate such characterization. Here, we used local weather data along with a mechanistic
model previously developed for influenza (16, 17) to capture the nonlinear response of
respiratory virus survival/transmission to humidity and temperature. In addition, we tested an
alternative seasonality form given the likely differences between SARS-CoV-2 and influenza
(e.g., likely higher infection risk for SARS-CoV-2 than influenza during the summer). When
incorporated in a model-inference framework and forecast system, forecasts with both
seasonality forms outperformed their counterpart without seasonality. Importantly,
improvements during the respiratory season were consistent throughout the pandemic,
including for the VOC waves, as well as for all 10 states with diverse climate conditions (Table
S4 and Fig S1). These findings indicate the robustness of the seasonality functions and the
importance of incorporating seasonality in COVID-19 forecast. More fundamentally, the results
support the idea that a common set of seasonal environmental/climate conditions influence
the transmission dynamics of respiratory viruses, including but not limited to SARS-CoV-2 and
influenza. Among the 10 states tested here, the transformed seasonality function tended to
outperform the fixed seasonality function based on parameters estimated for influenza, except
for Massachusetts and Michigan (Table S4). This difference in performance suggests there are
likely nuances in the seasonality of different respiratory viruses despite shared general
characteristics.
401
To focus on the above three challenges, in our retrospective forecasts, we used data/estimates
to account for several other factors shaping COVID-19 dynamics. These included behavioral
changes (including those due to NPIs), vaccination uptake, changing detection rates and hence
case ascertainment rate, as well as changes in infection fatality risk due to improvement of
treatment, vaccination, prior infection, and differences in the innate virulence of circulating
variants. For real-time forecast, such data and estimates would likely not be available and thus
forecast accuracy would likely be degraded. Nonetheless, as societies emerge from the acute
pandemic phase, many of these factors would likely reach certain norms (e.g., a relative stable
fraction of the population may continue to adopt preventive measures and detection rates may
stay low), reducing these uncertainties. Thus, though demonstrated mainly retrospectively, the
superior skill of the forecast methods developed here demonstrate means for generating more
accurate and sensible long-lead COVID-19 forecasts.
414
METHODS
Data used for model calibration

We used COVID-19 case and mortality data (26) – adjusted for circulating variants (27, 28) – to

capture transmission dynamics, mobility data (29) to represent concurrent NPIs, and

vaccination data (30, 31) to account for changes in population susceptibility due to vaccination.

For models including seasonality, we used weather data (i.e., temperature and humidity)(32,

33) to estimate the infection seasonality trends. See detailed data sources and processing in

the SI.

Model calibration before forecast generation (i.e. inference)

The model-inference system is similar to systems we developed to estimate changes in

transmissibility and immune erosion for SARS-CoV-2 VOCs including Alpha, Beta, Gamma, Delta,

and Omicron (17-19). However, to account for the fast waning of vaccine protection against

infection and differential vaccine effectiveness (VE) against different variants, here we

additionally accounted for variant-specific VE and waning vaccine protection against infection

per Eqn 1:

$$\begin{cases} \frac{dS}{dt} = \frac{R}{L_t} - \frac{b_t e_t m_t \beta_t IS}{N} - \varepsilon + \sum_{\tau=0}^{\tau=T} \rho_\tau V_{t-\tau} - \sum_{k=1}^{k=K} v_{k,t} \\ \frac{dE}{dt} = \frac{b_t e_t m_t \beta_t IS}{N} - \frac{E}{Z_t} + \varepsilon \\ \frac{dI}{dt} = \frac{E}{Z_t} - \frac{I}{D_t} \\ \frac{dR}{dt} = \frac{I}{D_t} - \frac{R}{L_t} \\ \frac{dV}{dt} = \sum_{k=1}^{k=K} v_{k,t} - \sum_{\tau=0}^{\tau=T} \rho_\tau V_{t-\tau} \end{cases} \quad \text{(Eqn 1)}$$

where S, E, I, R are the number of susceptible, exposed (but not yet infectious), infectious, and

recovered/deceased individuals; N is the population size; and ε is the number of travel-

imported infections. To account for changes due to circulating variants, Eqn 1 includes a time-

varying transmission rate β_t, latency period Z_t, infectious period D_t, and immunity period L_t. To

account for the impact of NPIs, Eqn 1 uses the relative population mobility (m_t) to adjust the

transmission rate and a scaling factor (e_t) to account for potential changes in effectiveness. To

account for vaccination and waning, V is the number of individuals vaccinated and protected

from infection, $v_{k,t}$ is the number of individuals immunized after the k-th dose at time t and ρ_τ

is the probability of losing vaccine protection τ days post vaccination (see SI and Table S5). As

described below, b_t is the seasonal infection risk at time t, depending on the seasonality

setting. We further computed the number of cases and deaths each week to match with the

observations using the model-simulated number of infections occurring each day (see the SI).

We ran the model jointly with the ensemble adjustment Kalman filter (EAKF (34)) and weekly

COVID-19 case and mortality data to estimate the model state variables (e.g., S, E, and I) and

parameters (e.g., β_t, Z_t, D_t, L_t, e_t). Briefly, the EAKF uses an ensemble of model realizations
(n=500 here), each with initial parameters and variables randomly drawn from a *prior* range
(Table S5). After model initialization, the system integrates the model ensemble forward in time
for a week (per Eqn 1) to compute the prior distribution for each model state variable, as well
as the model-simulated number of cases and deaths for that week. The system then combines
the prior estimates with the observed case and death data for the same week to compute the
posterior per Bayes' theorem (34). In addition, as in (17-19), during the filtering process, we
applied space-reprobing (35), i.e., random replacement of parameter values for a small fraction
of the model ensemble, to explore a wider range of parameter possibilities (Table S5). The
space-reprobing algorithm, along with the EAKF, allows the system to capture potential
changes over time (e.g., increased detection for variants causing more severe disease, or
increases in population susceptibility and transmission rate due to a new variant).
461
Variations in forecast systems (deflation, new variant, and seasonality settings)
In total, 12 forecast approaches were tested (3 deflation levels × 2 new variants settings × 3
seasonality forms). The deflation algorithm is patterned after covariance inflation, as used in
filtering methods (9, 10). However, unlike inflation applied during filtering (i.e., the model
training period via data assimilation), deflation is applied during the forecast period. As the
state variables change dynamically per the epidemic model (i.e., Eqn 1), the error of some
epidemic trajectories can amplify exponentially over time. Thus, here we applied deflation only
to the state variables (i.e., not to the model parameters), per:
$$x_i^{def} = \gamma(x_i - \bar{x}) + \bar{x}, i = 1, \dots, n \text{ (Eqn 2)}$$
where x_i is i-th ensemble member of a given state variable (here, S, E, or I) at each time step
during the forecast period, before the deflation; x_i^{def} is the corresponding "deflated" value; γ is
the deflation factor; and $\bar{x}$ is the ensemble mean of the state variable. Per Eqn 2, deflation
retains the ensemble mean, while reducing the ensemble spread to constrain error
accumulation. In this study, we tested three levels of deflation, by setting γ to 1 (i.e., no
deflation), 0.95, and 0.9, separately.
477
To anticipate and account for potential surges and their impact on COVID-19 epidemic
outcomes, we tested two approaches. The first, baseline approach simply assumes there are no
changes in the circulating variant during the forecast period. For this approach, the forecasts
were generated using the latest population susceptibility and transmission parameter estimates
at the point of forecast initiation. For the second, new variant approach, we devised a set of
heuristics to anticipate the likely timing and impact of new variant emergence during the
forecast period, as detailed in the SI.
485

Seasonality is incorporated in the epidemic model (Eqn 1) and applied throughout the model
calibration (i.e., inference) and forecast periods. Here, we tested three seasonality settings.
The first assumes no changes in seasonal risk of infection, by setting b_t in Eqn 1 to 1 for all
weeks (referred to as "no seasonality"). The second seasonality form (termed "fixed
seasonality) estimates the relative seasonality trend (b_t, same as in Eqn 1) using local humidity
and temperature data, based on the dependency of respiratory virus survival, including that of
SARS-CoV-2, to temperature and humidity (12, 17, 18, 36); see Eqn 3 and details in the SI. The
third seasonality setting (termed "transformed seasonality") transforms the b_t estimates to
allow flexibility in the seasonal trend, including the peak timing, the number of weeks during a
year with elevated infection risk, and the lowest risk level (see Eqn 4 and details in the SI). Due
to the lack of SARS-CoV-2 data to inform the parameter estimates, here we opted to optimize
the range for each parameter and used the best parameter ranges (see the SI and Fig S5) in the
transformed seasonality model in the main analysis.
499
Retrospective forecast
We tested the above 12 model-inference and forecast approaches (3 deflation levels × 2 new
variants settings × 3 seasonality forms) for 10 states, i.e., California, Florida, Iowa,
Massachusetts, Michigan, New York, Pennsylvania, Texas, Washington, and Wyoming. The 10
states span the 10 Health and Human Services (HHS) regions across the US, representing a wide
range of population characteristics and COVID-19 pandemic dynamics (Fig 1). For all states, we
generated retrospective forecasts of weekly cases and deaths 26 weeks (i.e., 6 months) into the
future for the non-Omicron period and the Omicron period, separately. For the non-Omicron
period, we initiated forecasts each week from the week of July 5, 2020 (i.e., after the initial
wave) through the week of August 15, 2021. Note that because each forecast spans 6 months,
the last forecasts initiated in mid-August 2021 extend to mid-Feb 2022, covering the entire
Delta wave (see Supplemental text for details). For the Omicron period, we initiated forecasts
starting 5 weeks after local detection of Omicron BA.1 (roughly in early December 2021,
depending on local data) through the week of September 25, 2022 (i.e., the last week of this
study).
515
To generate a forecast, we ran the model-inference system until the week of forecast, halted
the inference, and used the population susceptibility and transmissibility of the circulating
variant estimated at that time to predict cases and deaths for the following 26 weeks (i.e., 6
months). Because the infection detection rate and infection-fatality risk are linked to
observations of cases and deaths (see the SI), changes of these quantities during the forecast
period could obscure the underlying infection rate and forecast accuracy. Thus, for these two
parameters specifically, we used available model-inference estimates for corresponding
forecast period weeks to allow comparison of model-forecast cases and deaths with the data

while focusing on testing the accuracy of different model settings (e.g., seasonality and new
variant settings). For the same reason, we used all available mobility and vaccination data
including those for the forecast period, which would not be available in real time. For weeks in
the future without data/estimates, we used the latest estimates instead. To account for model
and filter stochasticity, we repeated each forecast 10 times, each time with initial parameters
and state variables randomly drawn from the same prior ranges.

To evaluate forecast performance, we computed both the log score based on the probabilistic
forecast and the accuracy of point prediction for 1) 1- to 26-week ahead prediction, and 2) peak
week, 3) peak intensity, and 4) cumulative total over the 26-week forecast period, for cases and
deaths, separately. Details are provided in the SI. Here, in brief, to compute the log score, we
first binned the forecast ensemble to generate the forecast probability distribution $\Pr(x)$, and
took the logarithm of the sum of $\Pr(x)$ across all related bins including the one including the
observation (bin^*) and two adjacent ones (bin^{*-1} and bin^{*+1}):
$$\log score = \log[\Pr(x)_{x\in bin^*} + \Pr(x)_{x\in bin^{*-1}} + \Pr(x)_{x\in bin^{*+1}}] \text{ (Eqn 5)}$$

For the accuracy of point prediction, we deemed a forecast accurate (assigned a value of 1) if
the median of the forecast ensemble is within ±1 week of the observed peak week or within
±25% of the observed case/death count, and inaccurate (assigned a value of 0) otherwise. As
noted above, when aggregated over multiple forecasts, the average would represent the
percentage of time a point prediction is accurate within these tolerances.

We compared the performance of each forecast approach (i.e., each of the 12 combinations of
deflation, new variant setting, and seasonality form) overall or by forecast target, segregated by
time period or respiratory virus season. To compute the overall score for each stratum, we
took the arithmetic mean of the log score or point prediction accuracy of forecasts generated
by each forecast system, either across all forecast targets or for each target, over 1) all forecast
weeks during the entire study period (i.e., July 2020 – September 2022), 2) the pre-Omicron
period and Omicron period, separately, 3) the respiratory virus season (mid-October to mid-
April, 6 months) and off season (the remaining 6 months), separately.

For pairwise comparison of forecast approaches, we computed the difference of log score or
accuracy by simple subtraction of the two arithmetic-means. Relative difference was also
computed. For the log score, the percent relative difference was computed as:
$$\% \ relative \ difference \ in \log score =$$
$$\frac{\exp (mean \ \log score \ of \ system \ a) - \exp (mean \log score \ of \ system \ b)}{\exp (mean \log score \ of \ system \ b)} \times 100\% \text{ (Eqn 6)}$$
As noted in (37), the exponent of the mean log score (Eqn 5) can be interpreted as the
probability correctly assigned to the bins containing the observations; thus Eqn 6 gives the

relative difference in the correctly assigned forecast probability. The percent relative difference
in accuracy of point prediction was computed as:

$$\% \; relative \; difference \; in \; accuracy =$$

$$\frac{mean \; accuracy \; of \; system \; a - mean \; accuracy \; of \; system \; b}{mean \; accuracy \; of \; system \; b} \times 100\% \; (Eqn \; 7)$$

In addition, we also computed the pair-wised difference of log score or accuracy (paired by
forecast week for each target and location) and used boxplots to examine the distributions
(see, e.g., Fig 6). We used the Wilcoxon rank sum test, a non-parametric statistical method, to
test whether there is a difference in the median of the pair-wised differences (38).

ARIMAX model forecast for comparison with approaches developed in this study
Auto-Regressive Integrated Moving Average (ARIMA) models and ARIMAX models (X represents
external predictors) are commonly used to forecast different outcomes. For comparison with
the approaches developed here, we also tested five ARIMA(X) models and used them to
generate retrospective forecasts per the same procedure described above. The first model (i.e.,
simple ARIMA model) used weekly case or mortality data alone for model training. The
remaining four models were ARIMAX models: 1) using case/mortality data and mobility data
including for the forecast period (i.e., X = mobility; referred to as "ARIMAX.MOB"); 2) using
case/mortality data and the estimated seasonal trend from the fixed seasonal model (i.e., X =
seasonality; referred to as "ARIMAX.SN"); 3) using case/mortality data, mobility data, and the
estimated seasonal trend (i.e., X = mobility and seasonality; referred to as "ARIMAX.MS"); and
4) using case/mortality data, mobility data, the estimated seasonal trend, and vaccination data
(i.e., X = mobility, seasonality, and vaccination; referred to as "ARIMAX.FULL"). For vaccination,
to account for the impact accumulated over time, we used cumulative vaccinations (here, in the
past 3 months for cases, and the past 9 months for deaths). For model optimization, we used
the "auto.arima" function of the "forecast" R package (39), which searches all possible models
within the specified order constraints (here, we used the default settings) to identify the best
ARIMA(X) model (here, based on the corrected Akaike information criterion by default).

For the five model forms, the ARIMAX.FULL model (i.e., including mobility, seasonality, and
vaccination) was only able to generate forecasts for less than half of the study weeks as the
auto.arima function was unable to identify parameters for this model. The other four models
were able to generate forecasts for most study weeks and across the entire study period, the
ARIMAX.SN (i.e., seasonality included) performed the best (see Table S5). As such, we used the
ARIMX.SN model as a benchmark model for comparison with approaches developed in this
study.

Preliminary assessment of real-time forecasts for the 2022 – 2023 respiratory virus season.

The last forecasts in this study were generated using all available data up to the week starting October 2, 2022 and spanned 6 months through the week starting March 26, 2023. These were real-time forecasts generated without future information. We assess these real-time forecasts using data downloaded on March 31, 2023 (1 day after the data release). Since these data may be revised in the future (*n.b.* data revision after the initial release has been common), we consider the assessment preliminary. As detailed in the SI, we used case and mortality data from the New York Times (NYT; (26)) for model calibration prior to generating the forecasts. However, in the six months since the initial study, NYT data have become more irregular for some states, likely due to infrequent data reporting and updating. As such, for this preliminary assessment, we instead used data from the Centers for Disease Control and Prevention (CDC)(40), except for mortality in Washington State for which the CDC data appeared to be misdated whereas NYT data and mortality data from the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (41) were consistent with each other. In addition, the CDC data were aggregated for each week from Thursday to Wednesday, rather than Sunday to Saturday. To enable the comparison, we thus shifted the dates of the CDC data 3 days.

All inference, forecast, and statistical analyses were carried out using the R language (https://www.r-project.org).

Acknowledgements: This study was supported by the National Institute of Allergy and Infectious Diseases (AI145883 and AI163023), the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE; contract no.: NU38OT00297), and the CDC Center for Forecasting and Outbreak Analytics (contract no.: 75D30122C14289).

Competing interests: JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.

References:
1. Borchering RK*, et al.* (2021) Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States, April-September 2021. *MMWR Morb Mortal Wkly Rep* 70(19):719-724.
2. Reich NG*, et al.* (2022) Collaborative Hubs: Making the Most of Predictive Epidemic Modeling. *American Journal of Public Health* 112(6):839-842.
3. Truelove S*, et al.* (2022) Projected resurgence of COVID-19 in the United States in July-December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination. *Elife* 11.
4. Nixon K*, et al.* (2022) An evaluation of prospective COVID-19 modelling studies in the USA: from data to science translation. *Lancet Digit Health* 4(10):e738-e747.

5.   Koelle K, Martin MA, Antia R, Lopman B, & Dean NE (2022) The changing epidemiology
of SARS-CoV-2. *Science* 375(6585):1116-1121.
6.   Markov PV, Katzourakis A, & Stilianakis NI (2022) Antigenic evolution will lead to new
SARS-CoV-2 variants with unpredictable severity. *Nat Rev Microbiol* 20(5):251-252.
7.   Shaman J, Kandula S, Yang W, & Karspeck A (2017) The use of ambient humidity
conditions to improve influenza forecast. *PLOS Computational Biology* 13(11):e1005844.
8.   Kramer SC & Shaman J (2019) Development and validation of influenza forecasting for
64 temperate and tropical countries. *Plos Computational Biology* 15(2).
9.   Anderson JL & Anderson SL (1999) A Monte Carlo Implementation of the Nonlinear
Filtering Problem to Produce Ensemble Assimilations and Forecasts. *Mon. Weather Rev.*
127(12):2741-2758.
10. Anderson JL (2007) An adaptive covariance inflation error correction algorithm for
ensemble filters. *Tellus A* 59(2):210-224.
11. Moriyama M, Hugentobler WJ, & Iwasaki A (2020) Seasonality of Respiratory Viral
Infections. *Annu Rev Virol* 7:83-101.
12. Morris DH*, et al.* (2021) Mechanistic theory predicts the effects of temperature and
humidity on inactivation of SARS-CoV-2 and other enveloped viruses. *Elife* 10.
13. Lowen AC, Mubareka S, Steel J, & Palese P (2007) Influenza Virus Transmission Is
Dependent on Relative Humidity and Temperature. *PLoS Pathog* 3(10):e151.
14. Yang W, Elankumaran S, & Marr LC (2012) Relationship between humidity and influenza
A viability in droplets and implications for influenza's seasonality. *PLoS One*
7(10):e46789.
15. Li Y, Wang X, & Nair H (2020) Global Seasonality of Human Seasonal Coronaviruses: A
Clue for Postpandemic Circulating Season of Severe Acute Respiratory Syndrome
Coronavirus 2? *J Infect Dis* 222(7):1090-1097.
16. Yuan H, Kramer SC, Lau EHY, Cowling BJ, & Yang W (2021) Modeling influenza
seasonality in the tropics and subtropics. *PLoS Comput Biol* 17(6):e1009050.
17. Yang W & Shaman J (2021) Development of a model-inference system for estimating
epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature*
Communications 12:5573.
18. Yang W & Shaman J (2022) COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta
variant and implications for vaccination. *J R Soc Interface* 19(191):20210900.
19. Yang W & Shaman JL (2022) COVID-19 pandemic dynamics in South Africa and
epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).
Elife 11.
20. statista (2020) Population density in the U.S. by federal states including the District of
Columbia in 2020. https://www.statista.com/statistics/183588/population-density-in-
the-federal-states-of-the-us/
21. Pei S, Cane MA, & Shaman J (2019) Predictability in process-based ensemble forecast of
influenza. *PLoS Comput Biol* 15(2):e1006783.
22. Pei S & Shaman J (2017) Counteracting structural errors in ensemble forecast of
influenza outbreaks. *Nat Commun* 8(1):925.
23. Choi YW, Tuel A, & Eltahir EAB (2021) On the Environmental Determinants of COVID-19
Seasonality. *Geohealth* 5(6):e2021GH000413.

24.   Merow C & Urban MC (2020) Seasonality and uncertainty in global COVID-19 growth
rates. *Proc Natl Acad Sci U S A* 117(44):27456-27464.
25.   Liu X*, et al.* (2021) The role of seasonality in the spread of COVID-19 pandemic. *Environ*
Res 195:110874.
26.   The New York Times (2022) Coronavirus (Covid-19) Data in the United States.
https://github.com/nytimes/covid-19-data
27.   Global Initiative on Sharing All Influenza Data (GISAID) (2021) Tracking of Variants.
https://www.gisaid.org/hcov19-variants/
28.   Anonymous (CoVariants. https://covariants.org
29.   Google Inc. (2020) Community Mobility Reports.
https://www.google.com/covid19/mobility/
30.   Our World in Data (2022) Data on COVID-19 (coronavirus) vaccinations by Our World in
Data. https://github.com/owid/covid-19-
data/blob/master/public/data/vaccinations/us_state_vaccinations.csv
31.   Mathieu E*, et al.* (2021) A global database of COVID-19 vaccinations. *Nature human*
behaviour 5(7):947-953.
32.   Iannone R (2020) Package 'stationaRy'. https://cran.r-
project.org/web/packages/stationaRy/stationaRy.pdf
33.   Iannone R (2020) stationaRy. https://github.com/rich-iannone/stationaRy
34.   Anderson JL (2001) An ensemble adjustment Kalman filter for data assimilation. *Mon.*
Weather Rev. 129(12):2884-2903.
35.   Yang W & Shaman J (2014) A simple modification for improving inference of non-linear
dynamical systems. *arXiv*:1403.6804.
36.   Biryukov J*, et al.* (2020) Increasing Temperature and Relative Humidity Accelerates
Inactivation of SARS-CoV-2 on Surfaces. *mSphere* 5(4):e00441-00420.
37.   Reich NG*, et al.* (2019) A collaborative multiyear, multimodel assessment of seasonal
influenza forecasting in the United States. *Proc Natl Acad Sci U S A* 116(8):3146-3154.
38.   Diebold FX & Mariano RS (1995) Comparing Predictive Accuracy. *J Bus Econ Stat*
13(3):253-263.
39.   Hyndman RJ & Khandakar Y (2008) Automatic time series forecasting: the forecast
package for R. *Journal of statistical software* 27:1-22.
40.   Centers for Disease Control and Prevention (2023) Weekly United States COVID-19
Cases and Deaths by State. https://data.cdc.gov/Case-Surveillance/Weekly-United-
States-COVID-19-Cases-and-Deaths-by-/pwn4-m3yp
41.   Anonymous (2021) COVID-19 Data Repository by the Center for Systems Science and
Engineering (CSSE) at Johns Hopkins University.
https://github.com/CSSEGISandData/COVID-19
720

Figure and Table Captions

Fig 1. Geospatial distribution of the 10 states and overall COVID-19 outcomes. Heatmaps show reported cumulative COVID-19 incidence rates (A) and COVID-19-associated mortality rates (B) in the 10 states included in this study. Line plots show reported weekly number of COVID-19 cases (C) and COVID-19-associated deaths (D) during the study period, for each state.

Fig 2. Example forecasts. Vertical dashed lines indicate the week of forecast. Dots show reported weekly cases per 1 million people; only those to the left of the vertical lines are used to calibrate the model and those to the right of the vertical lines are plotted for comparison. Blue lines and blue areas (line = median; darker blue = 50% CI; lighter blue = 80% CI) show model training estimates. Red lines and red areas (line = median; dark red = 50% CI; lighter red = 80% CI) show model forecasts using model settings as labeled in the subtitles.

Fig 3. Impact of deflation on forecast performance. Heatmaps show the differences in mean log score (A) or point prediction accuracy (B) between all forecast approaches with different deflation settings (deflation factor γ = 0.95 vs none in the 1st column, 0.9 vs none in the 2nd column, and 0.9 vs 0.95 in the 3rd column; see panel subtitles). Results are aggregated for each forecast approach (see specific settings of new variants and seasonality in the y-axis labels) and location (x-axis) over all forecast targets and forecast weeks, for cases (1st row) and deaths (2nd row), separately. For each pairwise comparison (e.g., 0.95 vs none), a positive difference in log score or point prediction accuracy indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Fig 4. Impact of new variant settings on forecast performance. Heatmaps show the differences in mean log score (A) or point prediction accuracy (B) between forecast approaches with vs without anticipation of new variant emergence. All forecasts here were generated using a deflation factor of 0.9. Results are aggregated for each forecast approach (see specific setting of seasonality in panel subtitles), variant wave (y-axis), and location (x-axis) over all forecast targets and forecast weeks for cases (1st row) and deaths (2nd row), separately. A positive difference indicates superior performance of the forecast approach with anticipation of new variant emergence.

Fig 5. Impact of seasonality settings on forecast performance. Heatmaps show the differences in mean log score (A) or point prediction accuracy (B), between pairs of forecast approaches with different seasonality settings (see panel subtitles). All forecasts here were generated using a deflation factor of 0.9 and the new variant setting. Results are aggregated for each forecast target (y-axis) and location (x-axis), over either the respiratory virus season (first 3 columns) or the off season (last 3 columns), for cases (1st row) and deaths (2nd row), separately. For each pairwise comparison (e.g., fixed vs no seasonality), a positive difference in log score or point prediction accuracy indicates the former approach (e.g., with fixed seasonality) outperforms the latter (e.g., with no seasonality).

Fig 6. Probabilistic forecast accuracy of the best-performing and baseline forecast approaches. Boxplots show the distributions of pair-wise difference in log score by variant period (A) or respiratory virus season (B; see panel subtitles). Results are aggregated by location (color-coded for each state) and forecast target (x-axis), for cases and deaths (see panel subtitles), separately. The numbers show the range of number of evaluations of each forecast target (e.g., 59 predictions of peak week during the pre-Omicron period, for each state; 16-20 predictions of peak week during the Omicron period, depending on the timing of Omicron detection in each state). A positive difference indicates superior log score of the best-performing forecast approach.

Fig 7. Point prediction accuracy of the best-performing and baseline forecast systems. Points show the average accuracy over all forecast weeks (A) or respiratory virus season (B). Results are aggregated by location (x-axis) and forecast target (panel subtitles) for cases (1st row) and deaths (2nd row, see panel subtitles) separately. Filled dots show the mean accuracy of forecasts generated using the baseline system; filled triangles show the accuracy of forecasts generated using the best-performing forecast system. The lines linking the two accuracies show the changes (mostly increases, as the triangles are more often above the dots), due to the combined application of the three proposed strategies (deflation, new variants, and transformed seasonality settings). Note all forecasts were generated retrospectively; to enable comparison of the model settings, mobility and vaccination data and estimates of infection detection rate and infection fatality risk during the forecast period were used (see main text for detail).

Fig 8. Real-time forecasts for the 2022-2023 respiratory virus season. The states are arranged based on accuracy of historical forecast (higher accuracy for those in the left panel and those on the top). In each panel, each row shows estimates and forecasts of weekly numbers of infections (1st column), cases (2nd column), or deaths (3rd column) for each state. Vertical dashed lines indicate the week of forecast initiation (i.e., October 2, 2022). Dots show reported weekly cases or deaths, including for the forecast period. Blue lines and blue areas (line = median; darker blue = 50% CI; lighter blue = 95% CI) show model training estimates. Red lines and red areas (line = median; dark red = 50% Predictive Interval; lighter red = 95% Predictive Interval) show model forecasts using the best-performing approach.

Fig 9. Real-time forecasts of cumulative infections, cases, and deaths during the 2022-2023 respiratory virus season. Box plots show distributions of predicted total number of infections (1st panel, scaled to population size; i.e. attack rate), cases (2nd panel, scaled to population size), and deaths (3rd panel, scaled per 1 million persons) from the week starting 10/2/2022 to the week starting 3/26/2023. Thick line = median; box edge = interquartile range; whisker = 95% prediction interval. The states (x-axis label) are arranged according to accuracy of historical forecast (higher accuracy from left to right). Red asterisks (*) show reported cumulative cases and deaths during the forecast period.

Table 1. Comparison of probabilistic forecast accuracy by the best-performing and the baseline forecast approaches. Numbers show the relative difference in mean log score computed using Eqn 6, the median of pairwise difference in log score (95% CI of the median); asterisk (*) indicates if the median is significantly >0 or <0 at the $\alpha = 0.05$ level, per a Wilcoxon rank sum test. Positive numbers indicate superior performance of the best-performing forecast approach.

Table 2. Comparison of point prediction accuracy by the best-performing and the baseline forecast approaches. Numbers show the mean point prediction accuracy of forecasts generated using the baseline v. the best-performing forecast approach; asterisk (*) indicates if the median of pairwise accuracy difference is significantly >0 or <0 at the $\alpha = 0.05$ level, per a Wilcoxon rank sum test. Note all forecasts were generated retrospectively; to enable comparison of forecast approaches, mobility and vaccination data and estimates of infection detection rate and infection fatality risk during the forecast period were used (see main text for detail).

Supporting Information (SI)

Supplemental methods. Addition details on 1) Data sources and processing; 2) Modeling of variant-specific vaccine effectiveness and waning vaccine protection against infection; 3) Observation model to account for under-detection and time-lags in COVID-19 outcomes; 4) Settings for anticipating the impact of new variants (the new variant approach); 5) The fixed seasonality model; 6) The transformed seasonality model; and 7) The retrospective forecast and forecast evaluation.

Fig S1. Comparison of seasonality forms. For each state (each panel), the blue line shows the estimated trend of seasonal infection risk using Eqns 3a-b and location weather data (temperature and humidity). Grey lines show 100 examples of the transformed seasonal trends per Eqns 4a-d with parameters randomly sampled from the best parameter ranges (Fig S4); the black line shows the mean of the 100 example trends.

Fig S2. Impact of deflation on probabilistic forecast of different targets. Heatmaps show differences in mean log score for cases (A) and deaths (B), between each forecast approach with different deflation settings (deflation factor $\gamma = 0.95$ vs none in the 1st row, 0.9 vs none in the 2nd row, and 0.9 vs 0.95 in the 3rd row; see panel subtitles). Results are aggregated over all forecast weeks for each type of target (y-axis), forecast approach (see specific settings of new variants and seasonality in subtitles), and location (x-axis). For each pairwise comparison (e.g., 0.95 vs none), a positive difference indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Fig S3. Impact of deflation on point estimate accuracy of different targets. Heatmaps show differences in forecast accuracy of point estimates for cases (A) and deaths (B), between each forecast approach with different deflation settings (deflation factor $\gamma = 0.95$ vs none in the 1st row, 0.9 vs none in the 2nd row, and 0.9 vs 0.95 in the 3rd row; see panel subtitles). Results are

aggregated over all forecast weeks for each type of target (y-axis), forecast approach (see specific settings of new variants and seasonality in subtitles), and location (x-axis). For each pairwise comparison (e.g., 0.95 vs none), a positive difference indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Fig S4. Comparison of forecast performance using the transformed seasonality function, with different parameter ranges. The parameter ranges are shown in x-axis labels for the three parameters in Eqn4a-d (from bottom to top: p_{shift}, δ, and $b_{t, lwr}$). 'x's indicate the best parameter ranges for the corresponding state.

Table S1. Impact of deflation. Numbers show the relative difference in mean log score computed using Eqn 6, or relative difference in mean point prediction accuracy computed using Eqn 7. For each pairwise comparison (e.g., 0.95 vs none), a positive difference indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Table S2. Impact of new variants settings. Numbers show the relative difference in mean log score computed using Eqn 6, or relative difference in mean point prediction accuracy computed using Eqn 7, by variant wave. A positive number indicates superior performance of the forecast approach with anticipation of new variant emergence.

Table S3. Impact of seasonality, aggregated over all 10 states. Numbers show the relative difference in mean log score or point prediction accuracy, the median of pair-wise difference in log score (95% CI of the median); asterisk (*) indicates if the median is significantly >0 or <0 at the α = 0.05 level, per a Wilcoxon rank sum test. A positive difference indicates superior log score or point prediction accuracy of the first listed approach; a negative difference indicates superior log score or point prediction accuracy of the second listed approach.

Table S4. Impact of seasonality, by state. Numbers show the relative difference in mean log score or point prediction accuracy, the median of pair-wise difference in log score (95% CI of the median); asterisk (*) indicates if the median is significantly >0 or <0 at the α = 0.05 level, per a Wilcoxon rank sum test. A positive difference indicates superior log score or point prediction accuracy of the first listed approach; a negative difference indicates superior log score or point prediction accuracy of the second listed approach.

Table S5. Comparison of forecast performance of the ARIMAX models. Only four models (see the top row for model names) are shown here because the fifth model (ARIMAX.FULL with vaccination included) was only able to generate forecasts for less than half of the study weeks; see details on the models in the main text. Numbers show the mean log score or point prediction accuracy of forecasts (specified in the "metric" column), aggregated across the entire study period and all locations for all forecast targets combined or individual forecast targets (specified in the "target" column). Bolded fonts indicate best performance (highest log score or accuracy).

Table S6. Comparison of forecast performance of the approaches developed in this study with the best-performing ARIMAX model. Numbers show the mean log score or point prediction accuracy of forecasts (specified in the "metric" column), aggregated across the entire study period and all locations for all forecast targets combined or individual forecast targets (specified in the "target" column). Bolded fonts indicate best performance (highest log score or accuracy).

Table S7. Preliminary assessment of the real-time forecasts initiated the week of October 2, 2022 for October 2022 – March 2023. The log score and accuracy were computed using reported case and mortality data downloaded on March 31, 2023 (see further details in the main text). As shown in Fig 8, COVID-19 mortality data in some states (e.g., Wyoming) were highly irregular during the forecast period, likely an artifact of reporting. Due to these potential data inaccuracies, the mortality-related log score and point prediction accuracy for these states are likely lower than the true values (to be obtained once more complete mortality data are available).

Table S8. Prior ranges for the parameters and variables used in the model-inference system. Parameters/state variables are initialized by drawing from uniform distributions specified in the rows labeled "Initialization". During the filtering process, space-reprobing is applied to explore the state space, i.e., a small fraction of the ensemble members are randomly replaced with values drawn from the uniform distributions specified in the rows labeled with "Space-reprobing".

Figures

Fig 1. Geospatial distribution of the 10 states and overall COVID-19 outcomes. Heatmaps show reported cumulative COVID-19 incidence rates (A) and COVID-19-associated mortality rates (B) in the 10 states included in this study. Line plots show reported weekly number of COVID-19 cases (C) and COVID-19-associated deaths (D) during the study period, for each state.

Fig 2. Example forecasts. Vertical dashed lines indicate the week of forecast. Dots show reported weekly cases per 1 million people; only those to the left of the vertical lines are used to calibrate the model and those to the right of the vertical lines are plotted for comparison. Blue lines and blue areas (line = median; darker blue = 50% CI; lighter blue = 80% CI) show model training estimates. Red lines and red areas (line = median; dark red = 50% CI; lighter red = 80% CI) show model forecasts using model settings as labeled in the subtitles.

Fig 3. Impact of deflation on forecast performance. Heatmaps show the differences in mean log score (A) or point prediction accuracy (B) between all forecast approaches with different deflation settings (deflation factor γ = 0.95 vs none in the 1st column, 0.9 vs none in the 2nd column, and 0.9 vs 0.95 in the 3rd column; see panel subtitles). Results are aggregated for each forecast approach (see specific settings of new variants and seasonality in the y-axis labels) and location (x-axis) over all forecast targets and forecast weeks, for cases (1st row) and deaths (2nd row), separately. For each pairwise comparison (e.g., 0.95 vs none), a positive difference in log score or point prediction accuracy indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Fig 4. Impact of new variant settings on forecast performance. Heatmaps show the differences in mean log score (A) or point prediction accuracy (B) between forecast approaches with vs without anticipation of new variant emergence. All forecasts here were generated using a deflation factor of 0.9. Results are aggregated for each forecast approach (see specific setting of seasonality in panel subtitles), variant wave (y-axis), and location (x-axis) over all forecast targets and forecast weeks for cases (1st row) and deaths (2nd row), separately. A positive difference indicates superior performance of the forecast approach with anticipation of new variant emergence.

Fig 5. Impact of seasonality settings on forecast performance. Heatmaps show the differences in mean log score (A) or point prediction accuracy (B), between pairs of forecast approaches with different seasonality settings (see panel subtitles). All forecasts here were generated using a deflation factor of 0.9 and the new variant setting. Results are aggregated for each forecast target (y-axis) and location (x-axis), over either the respiratory virus season (first 3 columns) or the off season (last 3 columns), for cases (1ˢᵗ row) and deaths (2ⁿᵈ row), separately. For each pairwise comparison (e.g., fixed vs no seasonality), a positive difference in log score or point prediction accuracy indicates the former approach (e.g., with fixed seasonality) outperforms the latter (e.g., with no seasonality).

Fig 6. Probabilistic forecast accuracy of the best-performing and baseline forecast approaches. Boxplots show the distributions of pair-wise difference in log score by variant period (A) or respiratory virus season (B; see panel subtitles). Results are aggregated by location (color-coded for each state) and forecast target (x-axis), for cases and deaths (see panel subtitles), separately. The numbers show the range of number of evaluations of each forecast target (e.g., 59 predictions of peak week during the pre-Omicron period, for each state; 16-20 predictions of peak week during the Omicron period, depending on the timing of Omicron detection in each state). A positive difference indicates superior log score of the best-performing forecast approach.

Fig 7. Point prediction accuracy of the best-performing and baseline forecast systems. Points show the average accuracy over all forecast weeks (A) or respiratory virus season (B). Results are aggregated by location (x-axis) and forecast target (panel subtitles) for cases (1st row) and deaths (2nd row, see panel subtitles) separately. Filled dots show the mean accuracy of forecasts generated using the baseline system; filled triangles show the accuracy of forecasts generated using the best-performing forecast system. The lines linking the two accuracies show the changes (mostly increases, as the triangles are more often above the dots), due to the combined application of the three proposed strategies (deflation, new variants, and transformed seasonality settings). Note all forecasts were generated retrospectively; to enable comparison of the model settings, mobility and vaccination data and estimates of infection detection rate and infection fatality risk during the forecast period were used (see main text for detail).

Fig 8. Real-time forecasts for the 2022-2023 respiratory virus season. The states are arranged based on accuracy of historical forecast (higher accuracy for those in the left panel and those on the top). In each panel, each row shows estimates and forecasts of weekly numbers of infections (1st column), cases (2nd column), or deaths (3rd column) for each state. Vertical dashed lines indicate the week of forecast initiation (i.e., October 2, 2022). Dots show reported weekly cases or deaths, including for the forecast period. Blue lines and blue areas (line = median; darker blue = 50% CI; lighter blue = 95% CI) show model training estimates. Red lines and red areas (line = median; dark red = 50% Predictive Interval; lighter red = 95% Predictive Interval) show model forecasts using the best-performing approach.

Fig 9. Real-time forecasts of cumulative infections, cases, and deaths during the 2022-2023 respiratory virus season. Box plots show distributions of predicted total number of infections (1st panel, scaled to population size; i.e. attack rate), cases (2nd panel, scaled to population size), and deaths (3rd panel, scaled per 1 million persons) from the week starting 10/2/2022 to the week starting 3/26/2023. Thick line = median; box edge = interquartile range; whisker = 95% prediction interval. The states (x-axis label) are arranged according to accuracy of historical forecast (higher accuracy from left to right). Red asterisks (*) show reported cumulative cases and deaths during the forecast period.

Tables

Table 1. Comparison of probabilistic forecast accuracy by the best-performing and the baseline forecast approaches. Numbers show the relative difference in mean log score computed using Eqn 6, the median of pairwise difference in log score (95% CI of the median); asterisk (*) indicates if the median is significantly >0 or <0 at the α = 0.05 level, per a Wilcoxon rank sum test. Positive numbers indicate superior performance of the best-performing forecast approach.

State	Measure	All	Pre-Omicron period	Omicron period	Respiratory season	Off season
All	Cases	63.6%, 0.34 (0.33, 0.35) *	85.3%, 0.43 (0.42, 0.44) *	27.2%, 0.21 (0.2, 0.22) *	105%, 0.53 (0.51, 0.54) *	40.6%, 0.22 (0.21, 0.23) *
All	Deaths	38%, 0.07 (0.06, 0.08) *	61.7%, 0.25 (0.24, 0.27) *	0.184%, -0.018 (-0.02, -0.016) *	84.5%, 0.42 (0.41, 0.44) *	13.7%, 0 (0, 0) *
California	Cases	46.3%, 0.18 (0.16, 0.21) *	65.8%, 0.26 (0.22, 0.32) *	15.9%, 0.11 (0.08, 0.14) *	93.7%, 0.35 (0.27, 0.43) *	21.2%, 0.13 (0.1, 0.15) *
California	Deaths	29.9%, 0.01 (0, 0.01) *	50.6%, 0.06 (0.04, 0.1) *	-1.26%, -0.028 (-0.032, -0.024) *	91.4%, 0.34 (0.26, 0.42) *	0.225%, -0.0095 (-0.013, -0.006) *
Florida	Cases	119%, 0.51 (0.46, 0.55) *	134%, 0.42 (0.37, 0.49) *	90.7%, 0.63 (0.57, 0.68) *	48.9%, 0.23 (0.2, 0.27) *	183%, 0.77 (0.71, 0.83) *
Florida	Deaths	84.5%, 0.23 (0.2, 0.26) *	117%, 0.28 (0.24, 0.33) *	33.6%, 0.11 (0.06, 0.18) *	58.5%, 0.27 (0.24, 0.31) *	104%, 0.17 (0.12, 0.26) *
Iowa	Cases	69.8%, 0.4 (0.37, 0.44) *	108%, 0.59 (0.55, 0.63) *	10.6%, 0.09 (0.06, 0.13) *	172%, 0.84 (0.77, 0.89) *	24.7%, 0.19 (0.16, 0.22) *
Iowa	Deaths	50.6%, 0.19 (0.16, 0.22) *	86.4%, 0.43 (0.39, 0.47) *	-4.49%, -0.024 (-0.03, -0.018) *	158%, 0.71 (0.66, 0.77) *	5.74%, 0 (0, 0.01) *
Massachusetts	Cases	84.1%, 0.42 (0.38, 0.46) *	131%, 0.66 (0.61, 0.72) *	17.6%, 0.17 (0.13, 0.2) *	213%, 0.91 (0.83, 0.99) *	29%, 0.16 (0.14, 0.19) *
Massachusetts	Deaths	40.1%, 0.04 (0.03, 0.06) *	68.9%, 0.28 (0.23, 0.34) *	-3.32%, -0.031 (-0.041, -0.022) *	130%, 0.61 (0.55, 0.67) *	0.439%, -0.005 (-0.009, -0.002) *
Michigan	Cases	76.4%, 0.48 (0.45, 0.51) *	86.9%, 0.49 (0.45, 0.52) *	55.9%, 0.46 (0.4, 0.51) *	119%, 0.62 (0.57, 0.68) *	53.2%, 0.39 (0.35, 0.42) *
Michigan	Deaths	36.9%, 0.12 (0.09, 0.14) *	60.9%, 0.32 (0.28, 0.35) *	-2.89%, -0.029 (-0.036, -0.022) *	85.6%, 0.48 (0.44, 0.52) *	12.2%, -0.0044 (-0.0095, -0.00048) *
New York	Cases	60.7%, 0.37 (0.34, 0.4) *	79.6%, 0.47 (0.44, 0.5) *	28.8%, 0.22 (0.19, 0.25) *	117%, 0.63 (0.57, 0.69) *	31.1%, 0.21 (0.18, 0.24) *
New York	Deaths	20.6%, 0.01 (0.01, 0.02) *	35.5%, 0.09 (0.06, 0.15) *	-4.31%, -0.025 (-0.032, -0.019) *	61.1%, 0.37 (0.33, 0.4) *	-0.7%, -0.0056 (-0.009, -0.0029) *
Pennsylvania	Cases	49.2%, 0.32 (0.3, 0.35) *	72.4%, 0.45 (0.42, 0.48) *	12.1%, 0.16 (0.13, 0.18) *	94.9%, 0.56 (0.52, 0.6) *	24.7%, 0.18 (0.16, 0.2) *
Pennsylvania	Deaths	30.5%, 0.12 (0.09, 0.15) *	51.7%, 0.3 (0.27, 0.33) *	-3.29%, -0.024 (-0.034, -0.016) *	71.9%, 0.41 (0.38, 0.44) *	8.45%, 0.01 (0, 0.01) *
Texas	Cases	74.3%, 0.32 (0.29, 0.36) *	120%, 0.51 (0.46, 0.57) *	9.88%, 0.07 (0.04, 0.12) *	158%, 0.64 (0.56, 0.71) *	34%, 0.18 (0.15, 0.21) *
Texas	Deaths	59.3%, 0.17 (0.14, 0.21) *	103%, 0.47 (0.42, 0.52) *	-1.88%, -0.012 (-0.015, -0.009) *	141%, 0.67 (0.6, 0.74) *	20.5%, 0.01 (0.01, 0.02) *
Washington	Cases	38.5%, 0.26 (0.23, 0.28) *	38.8%, 0.24 (0.21, 0.27) *	37.8%, 0.28 (0.25, 0.32) *	31.7%, 0.28 (0.24, 0.32) *	43.3%, 0.24 (0.2, 0.26) *

Washington	Deaths	13.8%, 0 (-0.0015, 0)	24.1%, 0.04 (0.02, 0.08) *	-4.22%, -0.028 (-0.034, -0.022) *	19.1%, 0.07 (0.03, 0.13) *	10.4%, -0.001 (-0.0029, 0.00093)
Wyoming	Cases	34.5%, 0.21 (0.19, 0.23) *	45.7%, 0.25 (0.23, 0.28) *	13.4%, 0.11 (0.07, 0.15) *	73.8%, 0.42 (0.38, 0.46) *	13.7%, 0.09 (0.07, 0.12) *
Wyoming	Deaths	26.8%, 0.05 (0.04, 0.08) *	42.7%, 0.19 (0.17, 0.22) *	-1.53%, -0.014 (-0.019, -0.01) *	73.9%, 0.36 (0.33, 0.41) *	3.06%, 0 (0.00094, 0.01) *

Table 2. Comparison of point prediction accuracy by the best-performing and the baseline forecast approaches. Numbers show the mean point prediction accuracy of forecasts generated using the baseline v. the best-performing forecast approach; asterisk (*) indicates if the median of pairwise accuracy difference is significantly >0 or <0 at the α = 0.05 level, per a Wilcoxon rank sum test. Note all forecasts were generated retrospectively; to enable comparison of forecast approaches, mobility and vaccination data and estimates of infection detection rate and infection fatality risk during the forecast period were used (see main text for detail).

State	Measure	1-8wk ahead	9-16wk ahead	17-26wk ahead	peak week	peak intensity	total
All	Cases	26% v 38% *	4% v 20% *	1% v 16% *	24% v 42% *	20% v 40% *	7% v 33% *
All	Deaths	39% v 48% *	7% v 25% *	1% v 16% *	35% v 56% *	30% v 50% *	9% v 36% *
California	Cases	27% v 36% *	8% v 17% *	3% v 12% *	26% v 34%	20% v 28% *	13% v 30% *
California	Deaths	38% v 45% *	10% v 23% *	4% v 11% *	37% v 56% *	23% v 29%	13% v 26% *
Florida	Cases	25% v 43% *	4% v 16% *	1% v 8% *	23% v 35% *	19% v 28% *	9% v 18% *
Florida	Deaths	40% v 51% *	6% v 25% *	1% v 8% *	27% v 31%	28% v 41% *	8% v 22% *
Iowa	Cases	24% v 37% *	1% v 25% *	0% v 21% *	32% v 41% *	22% v 38% *	6% v 44% *
Iowa	Deaths	37% v 47% *	4% v 26% *	0% v 23% *	34% v 58% *	22% v 41% *	6% v 46% *
Massachusetts	Cases	30% v 36% *	5% v 20% *	1% v 16% *	23% v 61% *	24% v 43% *	5% v 25% *
Massachusetts	Deaths	44% v 50% *	8% v 24% *	1% v 15% *	34% v 67% *	36% v 60% *	8% v 34% *
Michigan	Cases	28% v 40% *	2% v 21% *	0% v 19% *	15% v 37% *	20% v 30% *	1% v 27% *
Michigan	Deaths	43% v 52% *	4% v 26% *	0% v 18% *	38% v 43%	33% v 43% *	3% v 28% *
New York	Cases	30% v 42% *	2% v 24% *	0% v 18% *	26% v 59% *	24% v 59% *	3% v 39% *
New York	Deaths	44% v 51% *	7% v 28% *	0% v 20% *	44% v 79% *	40% v 78% *	7% v 47% *
Pennsylvania	Cases	27% v 37% *	4% v 22% *	0% v 23% *	24% v 32% *	20% v 59% *	4% v 50% *
Pennsylvania	Deaths	40% v 48% *	9% v 25% *	1% v 23% *	33% v 70% *	35% v 67% *	9% v 53% *
Texas	Cases	24% v 38% *	5% v 22% *	1% v 16% *	20% v 50% *	20% v 51% *	8% v 44% *
Texas	Deaths	39% v 49% *	7% v 26% *	1% v 19% *	34% v 46% *	33% v 61% *	13% v 50% *
Washington	Cases	24% v 37% *	6% v 17% *	1% v 17% *	22% v 24%	17% v 46% *	7% v 30% *
Washington	Deaths	39% v 51% *	7% v 25% *	2% v 18% *	32% v 45% *	24% v 57% *	9% v 31% *
Wyoming	Cases	23% v 32% *	5% v 19% *	0% v 10% *	28% v 42% *	15% v 20% *	8% v 25% *
Wyoming	Deaths	26% v 32% *	9% v 22% *	1% v 10% *	38% v 64% *	23% v 28% *	13% v 23% *

Supporting Information (SI)
for
Development of Accurate Long-lead COVID-19 Forecast
Wan Yang and Jeffrey Shaman

This document includes:

Supplemental Methods

Supplemental Figures S1 – S4

Supplemental Tables S1 – S8

SUPPLEMENTAL METHODS

Data sources and processing

For model calibration, we used reported COVID-19 case and mortality data to capture

transmission dynamics, mobility data to represent concurrent NPIs, and vaccination data to

account for changes in population susceptibility due to vaccination. State level COVID-19 case

and mortality data were sourced from the New York Times (NYT) (1) and included all variants. In

our previous studies, overall case/mortality data were sufficient to estimate key

epidemiological parameters when different VOC waves were separated in time (2-4); however,

in the US, the Omicron BA.1 wave overlapped substantially with the Delta wave during

November 2021 – January 2022, making inference challenging. Thus, here we separated the

forecasts into two periods (i.e., a pre-Omicron period combining all non-Omicron variants, and

an Omicron period combining all Omicron subvariants) and used variant-specific case and

mortality data for model training and forecast evaluation for each period. Specifically, we used

variant proportion data sourced from GISAID (5) and compiled by CoVariants.org (6) to

compute the weekly number of cases and deaths due to non-Omicron variants and Omicron,

separately (for simplicity, loosely referred to as variant-specific case and mortality data).

Because only biweekly variant proportion data at the state level were available from

CoVariants.org, we used a spline function to impute weekly variant proportion. To compute

weekly variant-specific cases, we multiplied the NYT weekly case data by the estimated weekly

variant proportion for the same week. To compute weekly variant-specific deaths, we

multiplied the NYT weekly mortality data by the estimated weekly variant proportion three

weeks later (i.e., assuming a 3-week lag from case detection to death; note the 3-week lag was

based on the approximate time lag between the peaks of incidence and mortality time series).

Mobility data were derived from Google Community Mobility Reports (7); we aggregated all

business-related categories (i.e., retail and recreational, grocery and pharmacy, transit stations,

and workplaces) in all locations in each state to weekly intervals. State level COVID-19

vaccination data were sourced from Our World in Data (8, 9). For models including seasonality,

weather data (i.e., temperature and humidity) were used to estimate infection seasonality

trends. Hourly surface station temperature and relative humidity came from the Integrated

Surface Dataset (ISD) maintained by the National Oceanic and Atmospheric Administration

(NOAA) and are accessible using the "stationaRy" R package (10, 11). We computed specific

humidity using temperature and relative humidity per the Clausius-Clapeyron equation (12).

We then aggregated these data for all weather stations in each state with measurements since

2000 and calculated the average for each week of the year during 2000-2020.

Modeling variant-specific vaccine effectiveness (VE) and waning vaccine protection against infection

As noted in the main text, the epidemic model in Eqn 1 includes vaccination and waning vaccine protection. Specifically, vaccination including boosters is represented using the term $\sum_{k=1}^{k=K} v_{k,t}$, where $v_{k,t}$ is the number of individuals immunized at time t, after the k-th dose (k = 1,…,3 for 2 primary and 1 booster dose here, excluding those immunized after previous doses). We computed $v_{k,t}$ using vaccination data and adjusted for the delay in antibody development (here, 14 days for the 1st dose and 7 days for subsequent doses) and variant specific VE (13-17). Note that while the 2nd booster dose has been administered for a subset of the population, such data have not been made publicly available and thus not included in our model. Further, given the 2nd dose and 3rd dose (i.e. 1st booster) were administered ~6 months apart (i.e., beyond the estimated VE duration against infection (16)), here we combined data for these two doses. In doing so, we have simplified the model and implicitly assumed that the 3rd dose resumed VE against infection to a level similar to the 2nd dose, as the same VE was applied (Table S8).

The model further accounts for waning of vaccine protection against infection, using the term $\sum_{\tau=0}^{\tau=T} \rho_\tau V_{t-\tau}$. We computed the total number who were vaccinated τ days ago and lost protection on day-t ($V_{t-\tau}$) per the VE waning probability (ρ_τ). The probabilities ρ_τ for time τ =0, …, T (T= the maximum duration from the earliest vaccination rollout; Table S8) were calculated using VE duration data (16) and $V_{t-\tau}$ was computed per line 5 of Eqn 1.

Observation model to account for under-detection and time-lags in COVID-19 outcomes

We computed the number of cases and deaths each week using the model-simulated number of infections occurring each day to match with the observations, as done in Yang et al. (18). Briefly, we included 1) a time-lag from infectiousness to detection (i.e., an infection being diagnosed as a case), drawn from a gamma distribution with a mean of $T_{d,mean}$ days and a standard deviation of $T_{d,sd}$ days, to account for delays in detection; 2) an infection-detection rate (r_t), i.e. the fraction of infections (including subclinical or asymptomatic infections) reported as cases, to account for under-detection; 3) a time-lag from infectiousness to death; and 4) an infection-fatality risk (IFR_t). Each week, the infection-detection rate (r_t), infection-fatality risk (IFR_t), and the two time-to-detection parameters ($T_{d,\ mean}$ and $T_{d,\ sd}$) were estimated along with other parameters (see main text). The time-lag from infectiousness to death during the pre-Omicron period was drawn from a gamma distribution with a mean of 14 days and a standard deviation of 14 days, roughly based on data from New York City (unpublished work). For the Omicron period, many deaths were identified posthumously; thus, it is difficult to estimate the time-lag from infection to death for Omicron infections. Here, based on the slightly longer time-lag between the peaks of case and mortality time series during the Omicron

76 period, we assumed a gamma distribution with a mean of 24 days (i.e., assuming an additional
77 10-day lag) and a standard deviation of 14 days.
78
To compute the model-simulated number of new cases each week, we multiplied the model-
simulated number of new infections per day by the infection-detection rate, and further
distributed these simulated cases in time per the distribution of time-from-infectiousness-to-
detection. Similarly, to compute the model-simulated deaths per week and account for delays
in time to death, we multiplied the simulated-infections by the IFR and then distributed these
simulated deaths in time per the distribution of time-from-infectious-to-death. We then
aggregated these daily numbers to weekly totals to match with the weekly case and mortality
data for model inference, as described in the main text.
87
Settings for anticipating the impact of new variants (the new variant approach)
The uncertainty due to the possible emergence or surge of new variants in the future is a major
challenge for long-lead COVID-19 forecast. To address this challenge, we devised a set of
heuristics to anticipate the likely timing and impact of new variant emergence during the
forecast period (i.e., the new variant approach). For the very near future (1- to 5 weeks), we
used available genomic sequencing data (see "Data sources and processing"). Specifically, we
first estimated the growth rate for each circulating variant based on variant proportion 6- to 2
weeks prior to the week of forecast initiation (i.e., assuming a 2-week lag for genomic data
collection); for simplicity, we used a log-linear model [i.e., log(variant proportion during week-t)
~ week-t]. If any variant had a high growth rate (here, arbitrarily set to 10% per week), we
deemed it a rising variant that could further affect the population susceptibility and overall
virus transmissibility. To anticipate its impact, we then used a smoothing spline to 1) project
when the variant would reach a 100% proportion and 2) project the number of weeks for the
variant to grow from 0% to 100%. The first estimate was then used to set the timing of the
continued impact and the second estimate was used to scale the increases in population
susceptibility. Here, arbitrarily, we assumed a baseline of 1.5 – 4.5% increase in susceptibility
for each week the new variant increased in proportion; however, if the estimated growth rate
(g) was >20%, to account for the faster growth, we scaled that baseline by a factor of $(1+g)/1.2$.
While the growth advantage of a new variant could also come from increased transmissibility,
for simplicity, here we opted to solely adjust for population susceptibility. In addition, given the
fast displacement of new variants, we opted not to use projected estimates 5 weeks beyond
the forecast week, i.e. these changes were only applied to the first 5 weeks of a forecast.
110
When genomic data could not be used (i.e. beyond the first 5 forecast weeks or when genomic
data were not available), we used the following heuristics to anticipate the likely timing and
impact of a new variant surge:

i) New variants tend to emerge after a recent large wave (here, defined arbitrarily as a 25%
attack rate over 3 months for the non-Omicron period, and a 33% attack rate over 2 months
for the Omicron period). We identified these times using estimated/forecasted infection
rates during the preceding months and the forecast period.
ii) New variants tend to emerge and/or become widespread during northern hemisphere
winter (December – February), southern hemisphere winter (June – August), and/or the
monsoon season (e.g. June – September in India) and could be introduced to the US during
these months. We identified these times using calendar month.
iii) During the above times with potential new variant emergence, the population susceptibility
and virus transmissibility could increase. Accordingly, to account for susceptibility changes,
we resampled half of the model ensemble to increase the population susceptibility by 2-9%
for weeks flagged per the conditions described in i and ii. However, this susceptibility
increase was only triggered when the mean population susceptibility was below 40% to
avoid over-adjustment. Similarly, to avoid the system being trapped in an outbreak-begets-
outbreak cycle, no further adjustments were made to susceptibility if a wave had been
forecast the prior weeks or the cumulative adjustment had exceeded a threshold (here, set
to 40% of the population over 26 weeks for pre-Omicron period and 60% for the Omicron
period). To account for transmissibility changes, we expanded the variance of the
transmission rate (i.e., β_t in Eqn 1) by applying an inflation factor of 1.3 (pre-Omicron
period) or 1.1 (Omicron period) to ensemble members falling between the 50th and 95th/90th
(pre-Omicron/Omicron period) percentiles (i.e., the ones with higher but not too extreme
values) for weeks identified per the conditions described in i and ii.
136

The fixed seasonality model
The fixed seasonality model represents the dependency of respiratory virus survival, including
that of SARS-CoV-2, to temperature and humidity (19, 20) per the following equations:

$$R_0(t) = [a_0 q^2(t) + a_1 q(t) + a_2][\frac{T_c}{T(t)}]^{T_{exp}} \text{ (Eqn 3a)}$$

$$b_t = \frac{R_0(t)}{\overline{R_0(t)}} \text{ (Eqn 3b)}$$

As described previously (3, 4), the seasonality function in Eqn 3a assumes that humidity has a
bimodal effect on seasonal risk of infection, with both low and high humidity conditions
favoring transmission [i.e., the parabola in the 1st set of brackets, where $q(t)$ is weekly specific
humidity measured by local weather stations and t = 1,...,52, i.e., week 1 to week 52 of the
year]; this effect is further modulated by temperature, with low temperatures promoting
transmission and temperatures above a certain threshold limiting transmission [i.e., the 2nd set
of brackets, where $T(t)$ is weekly temperature measured by local weather stations and T_c is the
threshold]. As SARS-CoV-2 specific parameters (a_0, a_1, a_2, T_c, and T_{exp} in Eqn 3a) are not
available, we used parameters estimated for influenza (21) and scaled the weekly outputs [i.e.,
$R_0(t)$] by the annual mean (i.e., $\overline{R_0}$) per Eqn 3b, as done in Yang and Shaman (4). In doing so,
the scaled outputs (b_t) are no longer specific to influenza; rather, they represent the *relative*,

seasonality-related transmissibility by week, general to viruses sharing similar seasonal

responses. The estimated relative seasonal trend, b_t, is then used to adjust the relative

transmission rate at time t in Eqn 1.

The transformed seasonality model

The transformed seasonality model transforms the b_t estimates from Eqn 3b to allow flexibility

in the seasonal trend. To do so, we include three parameters to fine tune the peak of the

seasonal trend (p_{shift}; i.e., the number of weeks earlier or later than the peak estimated for

influenza), the number of weeks during a year with $b_t > 1$ (δ; i.e., the duration with elevated

infection risk), and another parameter $b_{t,lwr}$ that adjusts the lowest b_t value. Specifically, the

transformation first adjusts values of b_t greater than 1, by shifting the timing by p_{shift} weeks

and adjusting the duration with elevated infection risk to δ, per

166
$$b'_{t\{b_t>1\}} = \frac{b_{t\{b_t>1\}+p_{shift}}}{\frac{n_{b_t>1}}{\delta}} \quad \text{(Eqn 4a)}$$

167 where $n_{b_t>1}$ is the number of weeks with $b_t > 1$ during the 1-year cycle. For weeks with $b_t \leq 1$,

168 the transformation adjusts the values, by shifting the timing by p_{shift} weeks and adjusting the

169 duration with lower infection risk to $52 - \delta$, per

170
$$b'_{t\{b_t\leq1\}} = \frac{b_{t\{b_t\leq1\}+p_{shift}}}{n_{b_t\leq1}/(52-\delta)} \quad \text{(Eqn 4b)}$$

171 The approach then further scales $b'_{t\{b_t\leq1\}}$ to increase the relative infection risk, per

172
$$b''_{t\{b_t\leq1\}} = 1 - (1 - b'_{t\{b_t\leq1\}})\left(min\left\{1, \frac{min\{b'_{t\{b_t\leq1\}}\}}{b_{t,lwr}}\right\}\right) \text{ (Eqn 4c)}$$

173 $b''_{t\{b_t>1\}} \equiv b'_{t\{b_t>1\}}$ and $b''_{t\{b_t\leq1\}}$ are then pooled together and scaled to have a mean of 1 over

174 the 1-year cycle, per

175
$$b'''_t = \frac{b''_t}{\overline{b''_t}} \text{ (Eqn 4d)}$$

There could be multiple combinations of the three parameters (i.e., p_{shift}, δ, and $b_{t,lwr}$). Due

to the lack of SARS-CoV-2 data to inform the parameter estimates, here we opted to optimize

the range for each parameter (as opposed to estimate specific best-fit parameters). Briefly, we

tested 2 levels (low vs. high) for each parameter and thus 8 in combination for each state (Fig

S5). We then identified the best range for each state based on forecast performance during the

2nd wave, i.e., before the surge of SARS-CoV-2 VOCs to minimize potential confounding. The

best parameter ranges (Fig S5) were then used in the transformed seasonality model in the

main analysis.

Additional details on the retrospective forecast and forecast evaluation

As noted in the main text, retrospective forecasts for the non-Omicron period were done
through the week of August 15, 2021. We stopped initiating the non-Omicron forecasts in mid-
August 2021 to allow at least a few weeks of Delta-related data to calibrate the model before
forecasting the Delta wave. However, a 6-month forecast initiated during mid-June – mid-
August 2021 would extend to mid-December 2021 – mid-Feb 2022, when Omicron BA.1 had
become predominant, depending on location; this overlap would lead to lower forecast
accuracy, since here we did not account for the emergence of Omicron BA.1 and fast
displacement of Delta. Given the low number of Delta-associated cases/deaths in 2022, weekly
targets (i.e., 1- to 26- week ahead prediction) for weeks in 2022 were excluded from the
evaluation; however, as Delta was the main circulating variant during the 6-month period for
these forecasts, all the overall targets (i.e., peak week, peak intensity, and cumulative total)
were evaluated based on Delta-specific data and included in the analysis.
199
Both the model inference and forecast were run with n = 500 model realizations (i.e., ensemble
members). The ensemble and its distribution provided probabilistic forecasts for 4 types of
targets here, i.e., 1-to 26-week ahead prediction, peak intensity, peak week, and cumulative
totals over the entire 26-week forecast period. For example, for the 1-week ahead prediction
(c_{t+1}), the fraction of ensemble members falling in a given bin $[c_i, c_{i+1})$ can be used to
represent the forecast probability density, i.e., $\Pr(c_{t+1} \in [c_i, c_{i+1})) = n_{\{c_{t+1} \geq c_i \ \& \ c_{t+1} < c_{i+1}\}}/n$.
Similarly, for the peak week prediction, predicted peak week by individual ensemble members
(p_w = 1, 2, …, 26) can be aggregated and the distribution can be used to represent the
probability distribution of the forecast, i.e., $\Pr(p_w = w) = n_{\{p_w = w\}}/n$.
209
The forecast probabilities can then be used to compute the log score for evaluation. To do so,
we first binned the forecast ensemble to generate the forecast probability distribution $\Pr(x)$,
e.g., $\Pr(c_{t+1})$ for 1-week ahead prediction and $\Pr(p_w)$ for peak week. Here, for cases, bins of
the weekly targets were set to $[0, 0.05\%), [0.05\%, 0.1\%), \dots, [0.95, 1\%),$ and $[1\%, 100\%]$ (i.e.,
increments of 0.05%, or 500 per million people, up to 1% of the population; and the rest
combined in the last bin); bins of cumulative cases over 26 weeks were set to $[0, 2\%),$
$[2\%, 4\%), \dots, [8\%, 10\%), [10\%, 15\%), [15\%, 20\%), \dots, [45\%, 50\%),$ and $[50\%, 100\%]$ (i.e.,
increments of 2% up to 10%, then increments of 5% up to 50% of the population; and the rest
combined in the last bin). For mortality, bins of the weekly targets were set to $[0, 0.001\%),$
$[0.001, 0.002), \dots, [0.019\%, 0.02\%),$ and $[0.02\%, 100\%]$ (i.e., increments of 0.001%, or 10 per
million people, up to 0.02% of the population; and the rest combined in the last bin); bins of
cumulative deaths over 26 weeks were set to $[0, 0.02\%), [0.02\%, 0.04\%), \dots, [0.08\%, 0.1\%),$
$[0.1\%, 0.15\%), [0.15\%, 0.2\%), \dots, [0.45\%, 0.5\%),$ and $[0.5\%, 100\%]$ (i.e., increments of 0.02%
up to 0.1%, then increments of 0.05% up to 0.5% of the population; and the rest combined in

the last bin). For the peak week of both cases and deaths, the bin size was set to 1 week. The
log score was then computed as:

$$\log score = \log[\Pr(x)_{x \in bin^*} + \Pr(x)_{x \in bin^{*-1}} + \Pr(x)_{x \in bin^{*+1}}] \ (Eqn\ 5)$$

where $\Pr(x)$ is the forecast probability for target x; bin^* is the bin that contains the observed
value for that target (see bin specifications above) and bin^{*-1} and bin^{*+1} are the two adjacent
bins. Note that, here we used smaller bins and deemed ensemble members falling within the
bin covering the observation and its two adjacent bins accurate, which is equivalent to using a
single larger bin spanning all those smaller bins. However, as the probabilistic forecasts (i.e.,
probabilities in each bin) were generated and stored before the final evaluation, using smaller
bins allowed more flexible post processing and evaluation if needed (e.g., the log score can be
computed based on a single small bin if preferred).

References:

1. The New York Times (2022) Coronavirus (Covid-19) Data in the United States.
    https://github.com/nytimes/covid-19-data
2. Yang W & Shaman JL (2022) COVID-19 pandemic dynamics in South Africa and
    epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).
    Elife 11.
3. Yang W & Shaman J (2022) COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta
    variant and implications for vaccination. *J R Soc Interface* 19(191):20210900.
4. Yang W & Shaman J (2021) Development of a model-inference system for estimating
    epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature
    Communications* 12:5573.
5. Global Initiative on Sharing All Influenza Data (GISAID) (2021) Tracking of Variants.
    https://www.gisaid.org/hcov19-variants/
6. Anonymous (CoVariants. https://covariants.org
7. Google Inc. (2020) Community Mobility Reports.
    https://www.google.com/covid19/mobility/
8. Our World in Data (2022) Data on COVID-19 (coronavirus) vaccinations by Our World in
    Data. https://github.com/owid/covid-19-
    data/blob/master/public/data/vaccinations/us_state_vaccinations.csv
9. Mathieu E*, et al.* (2021) A global database of COVID-19 vaccinations. *Nature human
    behaviour* 5(7):947-953.
10. Iannone R (2020) Package 'stationaRy'. https://cran.r-
    project.org/web/packages/stationaRy/stationaRy.pdf
11. Iannone R (2020) stationaRy. https://github.com/rich-iannone/stationaRy
12. Wallace J & Hobbs P (2006) *Atmospheric Science: An Introductory survey* (Academic
    Press, New York) 2nd Edition Ed p 504.

13. Polack FP*, et al.* (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
New Engl J Med.
14. Baden LR*, et al.* (2021) Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*
Engl J Med 384(5):403-416.
15. Haas EJ*, et al.* (2021) Impact and effectiveness of mRNA BNT162b2 vaccine against
SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
nationwide vaccination campaign in Israel: an observational study using national
surveillance data. *The Lancet* 397(10287):1819-1829.
16. UK Heath Security Agency (2022) COVID-19 vaccine surveillance report (Week 17, 28
April 2022).
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm
ent_data/file/1072064/Vaccine-surveillance-report-week-17.pdf
17. Kirsebom FCM*, et al.* (COVID-19 vaccine effectiveness against the omicron (BA.2) variant
in England. *The Lancet Infectious Diseases*.
18. Yang W*, et al.* (2021) Estimating the infection-fatality risk of SARS-CoV-2 in New York
City during the spring 2020 pandemic wave: a model-based analysis. *The Lancet.*
Infectious diseases 21(2):203-212.
19. Biryukov J*, et al.* (2020) Increasing Temperature and Relative Humidity Accelerates
Inactivation of SARS-CoV-2 on Surfaces. *mSphere* 5(4):e00441-00420.
20. Morris DH*, et al.* (2021) Mechanistic theory predicts the effects of temperature and
humidity on inactivation of SARS-CoV-2 and other enveloped viruses. *Elife* 10.
21. Yuan H, Kramer SC, Lau EHY, Cowling BJ, & Yang W (2021) Modeling influenza
seasonality in the tropics and subtropics. *PLoS Comput Biol* 17(6):e1009050.
287

Fig S1. Comparison of seasonality forms. For each state (each panel), the blue line shows the estimated trend of seasonal infection risk using Eqns 3a-b and location weather data (temperature and humidity). Grey lines show 100 examples of the transformed seasonal trends per Eqns 4a-d with parameters randomly sampled from the best parameter ranges (Fig S4); the black line shows the mean of the 100 example trends.

Fig S2. Impact of deflation on probabilistic forecast of different targets. Heatmaps show differences in mean log score for cases (A) and deaths (B), between each forecast approach with different deflation settings (deflation factor γ = 0.95 vs none in the 1ˢᵗ row, 0.9 vs none in the 2ⁿᵈ row, and 0.9 vs 0.95 in the 3ʳᵈ row; see panel subtitles). Results are aggregated over all forecast weeks for each type of target (y-axis), forecast approach (see specific settings of new variants and seasonality in subtitles), and location (x-axis). For each pairwise comparison (e.g., 0.95 vs none), a positive difference indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Fig S3. Impact of deflation on point estimate accuracy of different targets. Heatmaps show differences in forecast accuracy of point estimates for cases (A) and deaths (B), between each forecast approach with different deflation settings (deflation factor γ = 0.95 vs none in the 1st row, 0.9 vs none in the 2nd row, and 0.9 vs 0.95 in the 3rd row; see panel subtitles). Results are aggregated over all forecast weeks for each type of target (y-axis), forecast approach (see specific settings of new variants and seasonality in subtitles), and location (x-axis). For each pairwise comparison (e.g., 0.95 vs none), a positive difference indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Fig S4. Comparison of forecast performance using the transformed seasonality function, with different parameter ranges. The parameter ranges are shown in x-axis labels for the three parameters in Eqn4a-d (from bottom to top: p_{shift}, δ, and $b_{t,\,lwr}$). 'x's indicate the best parameter ranges for the corresponding state.

Table S1. Impact of deflation. Numbers show the relative difference in mean log score computed using Eqn 6, or relative difference in mean point prediction accuracy computed using Eqn 7. For each pairwise comparison (e.g., 0.95 vs none), a positive difference indicates the former approach (e.g., 0.95) outperforms the latter (e.g., none).

Metric	Measure	New variant setting	Seasonality setting	Pairwise comparison of deflation settings 0.95 vs none	0.9 vs none	0.9 vs 0.95
Log score	Cases	No new variants	No seasonality	20.1%	43.3%	19.4%
Log score	Cases	No new variants	Fixed seasonality	18.1%	34.2%	13.6%
Log score	Cases	No new variants	Transformed seasonality	19%	36.8%	15%
Log score	Cases	New variants	No seasonality	20.2%	38.7%	15.4%
Log score	Cases	New variants	Fixed seasonality	19.7%	35%	12.8%
Log score	Cases	New variants	Transformed seasonality	20%	35.9%	13.3%
Log score	Deaths	No new variants	No seasonality	7.67%	17.2%	8.85%
Log score	Deaths	No new variants	Fixed seasonality	7.8%	13.3%	5.1%
Log score	Deaths	No new variants	Transformed seasonality	7.94%	14.2%	5.75%
Log score	Deaths	New variants	No seasonality	7.43%	15.1%	7.19%
Log score	Deaths	New variants	Fixed seasonality	8.23%	13%	4.45%
Log score	Deaths	New variants	Transformed seasonality	8.4%	13.2%	4.45%
Accuracy	Cases	No new variants	No seasonality	28%	46.5%	14.4%
Accuracy	Cases	No new variants	Fixed seasonality	30.5%	38.6%	6.23%
Accuracy	Cases	No new variants	Transformed seasonality	47.8%	63.2%	10.4%
Accuracy	Cases	New variants	No seasonality	20.5%	32.5%	10%
Accuracy	Cases	New variants	Fixed seasonality	38.3%	47.2%	6.45%
Accuracy	Cases	New variants	Transformed seasonality	47%	55%	5.44%
Accuracy	Deaths	No new variants	No seasonality	15.5%	27%	9.98%
Accuracy	Deaths	No new variants	Fixed seasonality	20%	24.6%	3.84%
Accuracy	Deaths	No new variants	Transformed seasonality	26.8%	36%	7.22%
Accuracy	Deaths	New variants	No seasonality	14.7%	24.1%	8.18%
Accuracy	Deaths	New variants	Fixed seasonality	26.1%	34.1%	6.36%
Accuracy	Deaths	New variants	Transformed seasonality	31.2%	39.9%	6.62%

Table S2. Impact of new variants settings. Numbers show the relative difference in mean log score computed using Eqn 6, or relative difference in mean point prediction accuracy computed using Eqn 7, by variant wave. A positive number indicates superior performance of the forecast approach with anticipation of new variant emergence.

Metric	Measure	Seasonality setting	2nd wave	Alpha	Delta	Omicron
Log score	Cases	No seasonality	-2.09%	0.0271%	66.9%	10.5%
Log score	Cases	Fixed seasonality	-0.573%	-0.33%	119%	36.6%
Log score	Cases	Transformed seasonality	-1.07%	-1.03%	93.7%	34.1%
Log score	Deaths	No seasonality	-1.7%	0.00306%	19.1%	-5.31%
Log score	Deaths	Fixed seasonality	-0.387%	-0.291%	34.1%	-2.27%
Log score	Deaths	Transformed seasonality	-0.918%	-0.651%	27.8%	-2.73%
Accuracy	Cases	No seasonality	-1.52%	-0.11%	89.1%	37.1%
Accuracy	Cases	Fixed seasonality	0.578%	2.16%	16.8%	95.8%
Accuracy	Cases	Transformed seasonality	-1.33%	1.96%	26.1%	77.8%
Accuracy	Deaths	No seasonality	-1.45%	0.121%	69.9%	40.2%
Accuracy	Deaths	Fixed seasonality	-0.278%	2.73%	15.9%	67.7%
Accuracy	Deaths	Transformed seasonality	-1.31%	2.47%	22.5%	63.2%

Table S3. Impact of seasonality, aggregated over all 10 states. Numbers show the relative difference in mean log score or point prediction accuracy, the median of pair-wise difference in log score (95% CI of the median); asterisk (*) indicates if the median is significantly >0 or <0 at the α = 0.05 level, per a Wilcoxon rank sum test. A positive difference indicates superior log score or point prediction accuracy of the first listed approach; a negative difference indicates superior log score or point prediction accuracy of the second listed approach.

Wave	Season	Metric	Measure	Fixed vs no seasonality	Transformed vs no seasonality	Transformed vs fixed seasonality
All	All	Log score	Cases	-4.45%, -0.0075 (-0.012, -0.0034)*	-2.8%, -0.006 (-0.01, -0.002)*	1.73%, 0.01 (0, 0.01)*
All	All	Log score	Deaths	12.7%, 0.04 (0.04, 0.04)*	14.2%, 0.04 (0.04, 0.04)*	1.32%, -0.0015 (-0.002, -0.00054)*
All	All	Accuracy	Cases	20.4%, 10% (10%, 10%)	26.3%, 10% (10%, 10%)	4.92%, 0% (0%, 5%)*
All	All	Accuracy	Deaths	15.8%, 10% (9.99%, 10%)	18.2%, 10% (10%, 10%)	2.09%, 0% (0%, 0%)*
All	Respiratory season	Log score	Cases	39.8%, 0.19 (0.18, 0.2)	42.3%, 0.2 (0.18, 0.21)	1.8%, 0.01 (0, 0.01)*
All	Respiratory season	Log score	Deaths	37.4%, 0.16 (0.15, 0.17)	41.1%, 0.17 (0.15, 0.18)	2.64%, 0.01 (0, 0.01)*
All	Respiratory season	Accuracy	Cases	60.3%, 20% (20%, 25%)	75.3%, 25% (25%, 30%)	9.38%, 5.01% (5%, 5%)
All	Respiratory season	Accuracy	Deaths	47.3%, 25% (20%, 25%)	54.3%, 25% (25%, 30%)	4.76%, 5% (0%, 5%)
All	Off season	Log score	Cases	-25.9%, -0.14 (-0.14, -0.13)*	-24.6%, -0.14 (-0.16, -0.13)*	1.68%, 0 (0, 0.01)*
All	Off season	Log score	Deaths	-1.3%, 0.02 (0.02, 0.03)*	-0.86%, 0.02 (0.02, 0.02)*	0.444%, -0.0031 (-0.0036, -0.0025)*
All	Off season	Accuracy	Cases	-5.95%, -5% (-5%, 0%)*	-6.04%, 0% (-4.99%, 0%)*	-0.0987%, 0% (0%, 0.01%)*
All	Off season	Accuracy	Deaths	-6.77%, -5% (-5%, -4.99%)*	-7.64%, -4.99% (-5%, -5%)*	-0.94%, 0% (0%, 0.01%)*
2nd wave	Off season	Log score	Cases	32%, 0.22 (0.2, 0.24)	23.5%, 0.16 (0.14, 0.17)	-6.42%, -0.056 (-0.063, -0.051)*
2nd wave	Off season	Log score	Deaths	23.9%, 0.17 (0.16, 0.19)	17.1%, 0.13 (0.12, 0.14)	-5.5%, -0.048 (-0.052, -0.043)*
2nd wave	Off season	Accuracy	Cases	37.6%, 15% (15%, 20%)	35.6%, 20% (15%, 20%)	-1.43%, -0.01% (-5%, 0%)*

2nd wave	Off season	Accuracy	Deaths	45.6%, 25% (20%, 30%)	28.1%, 20% (15%, 20%)	-12%, -10% (-15%, -10%)*
Alpha	Off season	Log score	Cases	-9.35%, 0.01 (0, 0.01)*	-24.7%, -0.052 (-0.11, 0)*	-16.9%, -0.087 (-0.11, -0.052)*
Alpha	Off season	Log score	Deaths	-3.33%, 0.01 (0.01, 0.01)*	-10.8%, 0.01 (0.01, 0.02)*	-7.74%, 0 (0, 0)*
Alpha	Off season	Accuracy	Cases	-42.4%, -30% (-35%, -25%)*	-39.8%, -30% (-35%, -25%)*	4.52%, 5% (-0.01%, 5.01%)
Alpha	Off season	Accuracy	Deaths	-28.5%, -25% (-25%, -20%)*	-33.8%, -30% (-30%, -25%)*	-7.53%, -5.01% (-10%, 0%)*
Delta	Off season	Log score	Cases	-49.6%, -0.57 (-0.61, -0.55)*	-35.4%, -0.32 (-0.35, -0.3)*	28.2%, 0.25 (0.23, 0.26)
Delta	Off season	Log score	Deaths	-12%, 0.02 (0.02, 0.02)*	-6.52%, 0.02 (0.02, 0.02)*	6.28%, -0.0024 (-0.003, -0.0015)*
Delta	Off season	Accuracy	Cases	-55.8%, -25% (-25%, -20%)*	-50%, -20% (-25%, -20%)*	13.1%, 4.99% (0%, 5%)*
Delta	Off season	Accuracy	Deaths	-50.3%, -25% (-25%, -20%)*	-43.2%, -20% (-20%, -15%)*	14.5%, 5% (4.99%, 10%)
Omicron	Off season	Log score	Cases	-19.5%, -0.15 (-0.16, -0.14)*	-24%, -0.16 (-0.17, -0.15)*	-5.68%, -0.013 (-0.017, -0.0085)*
Omicron	Off season	Log score	Deaths	4.77%, 0.03 (0.03, 0.03)*	3.84%, 0.02 (0.02, 0.03)*	-0.887%, -0.0035 (-0.0041, -0.003)*
Omicron	Off season	Accuracy	Cases	4.46%, 0.01% (0%, 5%)*	2.52%, 0% (0%, 5%)*	-1.86%, -0.01% (0%, 0%)*
Omicron	Off season	Accuracy	Deaths	-1.59%, 0% (0%, 0%)*	-1.78%, 0% (0%, 0%)*	-0.191%, -0.01% (0%, 0%)*

Table S4. Impact of seasonality, by state. Numbers show the relative difference in mean log score or point prediction accuracy, the median of pair-wise difference in log score (95% CI of the median); asterisk (*) indicates if the median is significantly >0 or <0 at the α = 0.05 level, per a Wilcoxon rank sum test. A positive difference indicates superior log score or point prediction accuracy of the first listed approach; a negative difference indicates superior log score or point prediction accuracy of the second listed approach.

State	Season	Metric	Measure	Fixed vs no seasonality	Transformed vs no seasonality	Transformed vs fixed seasonality
California	All	Log score	Cases	-7.14%, -0.042 (-0.062, -0.024)*	-1.53%, -0.028 (-0.045, -0.013)*	6.04%, 0.02 (0.01, 0.02)*
California	All	Log score	Deaths	16.7%, 0.04 (0.04, 0.05)*	21.4%, 0.04 (0.03, 0.04)*	3.96%, 0 (0, 0.01)*
California	All	Accuracy	Cases	13.1%, 5% (0%, 9.99%)	11.3%, 5% (0%, 10%)	-1.6%, 0% (0%, 0%)*
California	All	Accuracy	Deaths	4.74%, 0% (0.01%, 5%)*	1.86%, 0% (-0.01%, 5%)*	-2.75%, 0% (-4.99%, 0%)*
California	Respiratory season	Log score	Cases	42.5%, 0.17 (0.13, 0.22)	56.7%, 0.24 (0.19, 0.3)	9.96%, 0.05 (0.04, 0.06)*
California	Respiratory season	Log score	Deaths	48.4%, 0.21 (0.15, 0.3)	60%, 0.27 (0.19, 0.37)	7.8%, 0.03 (0.02, 0.04)*
California	Respiratory season	Accuracy	Cases	51.9%, 20% (15%, 20%)	58.9%, 20% (15%, 25%)	4.61%, 4.99% (-0.01%, 5%)*
California	Respiratory season	Accuracy	Deaths	27.9%, 15% (10%, 20%)	22.4%, 10% (5%, 15%)	-4.33%, -5% (-10%, 0%)*
California	Off season	Log score	Cases	-30.3%, -0.17 (-0.2, -0.14)*	-27.9%, -0.19 (-0.23, -0.16)*	3.49%, -0.0024 (-0.013, 0)*
California	Off season	Log score	Deaths	-0.598%, 0.03 (0.02, 0.03)*	0.856%, 0.02 (0.02, 0.03)*	1.46%, -1e-05 (-0.0014, 0.00098)*
California	Off season	Accuracy	Cases	-11%, -5% (-10%, 0%)*	-18.4%, -9.99% (-15%, -5.01%)*	-8.21%, -5% (-10%, 0%)*
California	Off season	Accuracy	Deaths	-8.26%, -5% (-10%, 0%)*	-9.65%, -5% (-10%, -5%)*	-1.52%, 0% (-4.99%, 5%)*
Florida	All	Log score	Cases	-12.6%, -0.02 (-0.032, -0.01)*	-6.11%, 0.001 (-0.0085, 0.01)*	7.47%, 0.03 (0.02, 0.04)*
Florida	All	Log score	Deaths	0.697%, 0.02 (0.01, 0.02)*	4.42%, 0.02 (0.02, 0.03)*	3.7%, 0.01 (0.01, 0.01)*
Florida	All	Accuracy	Cases	8.52%, 5% (5%, 10%)	11.5%, 5% (5%, 10%)	2.74%, 0% (0%, 5%)*
Florida	All	Accuracy	Deaths	3.73%, 5% (0%, 5.01%)	4.9%, 5% (0%, 5.01%)	1.14%, 0% (0%, 0%)*
Florida	Respiratory season	Log score	Cases	-2.01%, 0.03 (0.02, 0.05)*	1.72%, 0.04 (0.02, 0.05)*	3.81%, 0.02 (0.01, 0.04)*

Florida	Respiratory season	Log score	Deaths	2.77%, 0.05 (0.04, 0.06)	8.52%, 0.06 (0.04, 0.07)	5.59%, 0.03 (0.02, 0.04)*
Florida	Respiratory season	Accuracy	Cases	19%, 10% (9.99%, 15%)	20.7%, 15% (10%, 20%)	1.44%, 0% (-5%, 5%)*
Florida	Respiratory season	Accuracy	Deaths	11.8%, 10% (9.99%, 15%)	12.9%, 10% (5%, 15%)	0.958%, 0% (-5%, 4.99%)*
Florida	Off season	Log score	Cases	-19.1%, -0.066 (-0.088, -0.046)*	-11%, -0.02 (-0.037, -0.0059)*	10%, 0.03 (0.02, 0.05)*
Florida	Off season	Log score	Deaths	-0.675%, 0.01 (0.01, 0.01)*	1.75%, 0.01 (0.01, 0.02)*	2.44%, 0 (0.00049, 0)*
Florida	Off season	Accuracy	Cases	2.1%, 0% (0%, 5%)*	5.84%, 5% (0%, 5%)	3.66%, 0% (0.01%, 5%)*
Florida	Off season	Accuracy	Deaths	-1.82%, 0% (-5%, 0%)*	-0.565%, 0% (0%, 4.99%)*	1.28%, 0.01% (0%, 4.99%)*
Iowa	All	Log score	Cases	1.02%, 0.02 (0.01, 0.03)*	6.96%, 0.03 (0.02, 0.04)*	5.89%, 0.02 (0.01, 0.03)*
Iowa	All	Log score	Deaths	23.6%, 0.07 (0.06, 0.08)	25.7%, 0.06 (0.05, 0.07)	1.64%, -0.001 (-0.0031, 5e-04)*
Iowa	All	Accuracy	Cases	12.9%, 5% (0%, 10%)	28.3%, 10% (10%, 15%)	13.7%, 10% (5%, 10%)
Iowa	All	Accuracy	Deaths	17.8%, 10% (5%, 10%)	22.7%, 10% (10%, 15%)	4.19%, 5% (0.01%, 5.01%)
Iowa	Respiratory season	Log score	Cases	77.8%, 0.47 (0.4, 0.53)	77.4%, 0.48 (0.42, 0.54)	-0.246%, 0.01 (-0.003, 0.02)*
Iowa	Respiratory season	Log score	Deaths	72.9%, 0.38 (0.31, 0.46)	76.2%, 0.44 (0.36, 0.5)	1.95%, 0.01 (-0.001, 0.02)*
Iowa	Respiratory season	Accuracy	Cases	71.5%, 25% (20%, 25%)	112%, 35% (30%, 40%)	23.4%, 15% (9.99%, 15%)
Iowa	Respiratory season	Accuracy	Deaths	81%, 35% (30%, 35%)	88.7%, 35% (30%, 40%)	4.26%, 5% (0.01%, 10%)
Iowa	Off season	Log score	Cases	-30.2%, -0.11 (-0.14, -0.076)*	-23.2%, -0.076 (-0.1, -0.05)*	10.1%, 0.02 (0.01, 0.03)*
Iowa	Off season	Log score	Deaths	-0.723%, 0.03 (0.03, 0.04)*	0.71%, 0.03 (0.03, 0.03)*	1.44%, -0.0035 (-0.0055, -0.0025)*
Iowa	Off season	Accuracy	Cases	-17.6%, -10% (-15%, -5%)*	-14.9%, -10% (-10%, -4.99%)*	3.29%, 0% (0%, 5%)*
Iowa	Off season	Accuracy	Deaths	-18.8%, -10% (-15%, -10%)*	-15.5%, -10% (-15%, -5.01%)*	4.1%, 0% (0%, 5%)*

Massachusetts	All	Log score	Cases	8.31%, 0.05 (0.03, 0.07)	4.64%, 0.02 (0, 0.03)*	-3.39%, -0.03 (-0.038, -0.023)*
Massachusetts	All	Log score	Deaths	30%, 0.11 (0.1, 0.12)	28.8%, 0.08 (0.07, 0.09)	-0.937%, -0.015 (-0.018, -0.012)*
Massachusetts	All	Accuracy	Cases	49.1%, 20% (15%, 25%)	33.5%, 15% (10%, 15%)	-10.4%, -10% (-10%, -5%)*
Massachusetts	All	Accuracy	Deaths	34.7%, 20% (15%, 20%)	28.1%, 15% (10%, 20%)	-4.87%, -5% (-5%, 0%)*
Massachusetts	Respiratory season	Log score	Cases	83.6%, 0.5 (0.44, 0.57)	78%, 0.45 (0.39, 0.52)	-3.05%, -0.034 (-0.044, -0.023)*
Massachusetts	Respiratory season	Log score	Deaths	72.7%, 0.42 (0.34, 0.49)	71%, 0.41 (0.35, 0.48)	-0.976%, -0.021 (-0.028, -0.015)*
Massachusetts	Respiratory season	Accuracy	Cases	121%, 35% (35%, 40%)	99.7%, 35% (30%, 40%)	-9.73%, -10% (-10%, -5%)*
Massachusetts	Respiratory season	Accuracy	Deaths	68.3%, 30% (25%, 35%)	56.7%, 25% (25%, 30%)	-6.9%, -5% (-10%, -5%)*
Massachusetts	Off season	Log score	Cases	-24%, -0.074 (-0.11, -0.046)*	-26.8%, -0.18 (-0.24, -0.14)*	-3.62%, -0.026 (-0.036, -0.017)*
Massachusetts	Off season	Log score	Deaths	7.39%, 0.05 (0.04, 0.06)*	6.42%, 0.03 (0.03, 0.04)*	-0.91%, -0.012 (-0.014, -0.0096)*
Massachusetts	Off season	Accuracy	Cases	3.66%, 0% (0%, 5%)*	-8.13%, -4.99% (-10%, 0%)*	-11.4%, -5% (-10%, -5%)*
Massachusetts	Off season	Accuracy	Deaths	7.54%, 5% (0.01%, 9.99%)	5.05%, 5% (0%, 5%)	-2.31%, 0% (-5%, 0%)*
Michigan	All	Log score	Cases	0.571%, -0.0055 (-0.024, 0.01)*	-9.27%, -0.034 (-0.054, -0.015)*	-9.79%, -0.03 (-0.038, -0.023)*
Michigan	All	Log score	Deaths	16.8%, 0.06 (0.05, 0.08)	7.52%, 0.04 (0.03, 0.05)*	-7.95%, -0.032 (-0.036, -0.028)*
Michigan	All	Accuracy	Cases	26.8%, 10% (9.99%, 15%)	20.5%, 10% (5%, 10%)	-5.01%, -5% (-5%, 0%)*
Michigan	All	Accuracy	Deaths	21.6%, 10% (9.99%, 15%)	10.2%, 5% (5%, 9.99%)	-9.42%, -5% (-9.99%, -5%)*
Michigan	Respiratory season	Log score	Cases	38.8%, 0.24 (0.19, 0.29)	29.1%, 0.19 (0.15, 0.24)	-7.03%, -0.036 (-0.044, -0.027)*
Michigan	Respiratory season	Log score	Deaths	38.7%, 0.19 (0.15, 0.24)	33%, 0.16 (0.12, 0.2)	-4.09%, -0.036 (-0.043, -0.028)*
Michigan	Respiratory season	Accuracy	Cases	116%, 35% (30%, 40%)	84.3%, 25% (25%, 30%)	-14.6%, -10% (-15%, -5%)*

Michigan	Respiratory season	Accuracy	Deaths	83.9%, 40% (35%, 40%)	44.1%, 25% (20%, 25%)	-21.6%, -20% (-20%, -15%)*
Michigan	Off season	Log score	Cases	-18.6%, -0.14 (-0.18, -0.11)*	-28%, -0.21 (-0.24, -0.16)*	-11.6%, -0.029 (-0.042, -0.017)*
Michigan	Off season	Log score	Deaths	4.38%, 0.04 (0.03, 0.05)*	-6.47%, 0.02 (0.01, 0.03)*	-10.4%, -0.028 (-0.032, -0.024)*
Michigan	Off season	Accuracy	Cases	-16.4%, -10% (-10%, -5%)*	-10.6%, -5.01% (-9.99%, 0%)*	7.01%, 5% (0%, 10%)
Michigan	Off season	Accuracy	Deaths	-18%, -10% (-15%, -10%)*	-11.4%, -5% (-10%, 0%)*	8.01%, 5.01% (0%, 10%)
New York	All	Log score	Cases	-3.26%, 0.01 (5.9e-06, 0.02)*	-4.56%, -0.002 (-0.02, 0.01)*	-1.34%, -0.0065 (-0.014, 6.4e-05)*
New York	All	Log score	Deaths	19%, 0.08 (0.07, 0.09)	17.9%, 0.06 (0.05, 0.07)	-0.852%, -0.011 (-0.014, -0.0086)*
New York	All	Accuracy	Cases	30.7%, 15% (10%, 15%)	51%, 20% (20%, 25%)	15.6%, 10% (5%, 15%)
New York	All	Accuracy	Deaths	21.7%, 10% (10%, 15%)	32.1%, 20% (15%, 20%)	8.58%, 10% (5%, 10%)
New York	Respiratory season	Log score	Cases	44.9%, 0.24 (0.21, 0.28)	44.3%, 0.24 (0.2, 0.28)	-0.435%, -0.007 (-0.019, 0)*
New York	Respiratory season	Log score	Deaths	37.8%, 0.21 (0.18, 0.25)	37.8%, 0.21 (0.17, 0.24)	-0.00206%, -0.0056 (-0.014, 0)*
New York	Respiratory season	Accuracy	Cases	62.7%, 25% (20%, 30%)	100%, 35% (30%, 40%)	22.9%, 15% (10%, 20%)
New York	Respiratory season	Accuracy	Deaths	51.3%, 25% (20%, 30%)	80.5%, 40% (35%, 40%)	19.3%, 15% (15%, 20%)
New York	Off season	Log score	Cases	-26.3%, -0.11 (-0.14, -0.085)*	-27.7%, -0.2 (-0.25, -0.15)*	-1.94%, -0.0074 (-0.017, 2.2e-05)*
New York	Off season	Log score	Deaths	7.78%, 0.05 (0.05, 0.06)	6.25%, 0.04 (0.03, 0.04)*	-1.42%, -0.012 (-0.014, -0.01)*
New York	Off season	Accuracy	Cases	6.51%, 5% (-0.01%, 10%)	14%, 5% (0%, 10%)	7.02%, 5% (0%, 10%)
New York	Off season	Accuracy	Deaths	-0.706%, -0.01% (-4.99%, 5%)*	-4.44%, -5% (-10%, 0%)*	-3.76%, -5% (-5%, 0%)*
Pennsylvania	All	Log score	Cases	-5.3%, -0.008 (-0.026, 0.01)*	-5.72%, 0.01 (-0.0085, 0.02)*	-0.438%, -0.0039 (-0.011, 0)*
Pennsylvania	All	Log score	Deaths	13.8%, 0.07 (0.06, 0.08)	12.9%, 0.06 (0.05, 0.07)	-0.791%, -0.012 (-0.016, -0.009)*

Pennsylvania	All	Accuracy	Cases	29.7%, 10% (10%, 15%)	47.5%, 20% (15%, 20%)	13.7%, 10% (5%, 10%)
Pennsylvania	All	Accuracy	Deaths	29.4%, 15% (10%, 20%)	36.4%, 20% (15%, 20%)	5.39%, 5% (0%, 9.99%)
Pennsylvania	Respiratory season	Log score	Cases	38.5%, 0.18 (0.14, 0.22)	38.6%, 0.2 (0.17, 0.23)	0.0339%, -0.003 (-0.016, 0.01)*
Pennsylvania	Respiratory season	Log score	Deaths	36.2%, 0.15 (0.12, 0.18)	35.4%, 0.14 (0.11, 0.16)	-0.636%, -0.017 (-0.028, -0.006)*
Pennsylvania	Respiratory season	Accuracy	Cases	48.9%, 20% (15%, 25%)	99.6%, 35% (30%, 40%)	34.1%, 20% (15%, 25%)
Pennsylvania	Respiratory season	Accuracy	Deaths	50.6%, 25% (20%, 30%)	76.7%, 40% (35%, 40%)	17.4%, 15% (10%, 20%)
Pennsylvania	Off season	Log score	Cases	-26.7%, -0.18 (-0.23, -0.14)*	-27.2%, -0.19 (-0.24, -0.14)*	-0.754%, -0.0046 (-0.012, 0)*
Pennsylvania	Off season	Log score	Deaths	0.845%, 0.05 (0.04, 0.06)*	-0.0572%, 0.04 (0.04, 0.05)*	-0.895%, -0.011 (-0.014, -0.0085)*
Pennsylvania	Off season	Accuracy	Cases	13%, 5% (0.01%, 9.99%)	2.05%, 0% (-0.01%, 4.99%)*	-9.71%, -5.01% (-10%, -4.99%)*
Pennsylvania	Off season	Accuracy	Deaths	11.1%, 5% (0%, 10%)	1.46%, 0% (-4.99%, 5%)*	-8.66%, -5% (-10%, -5%)*
Texas	All	Log score	Cases	-9.81%, -0.02 (-0.043, -0.00054)*	1.82%, 0.01 (-0.0066, 0.02)*	12.9%, 0.06 (0.05, 0.07)
Texas	All	Log score	Deaths	6.34%, 0.03 (0.02, 0.03)*	15.6%, 0.03 (0.02, 0.03)*	8.68%, 0.01 (0.01, 0.01)*
Texas	All	Accuracy	Cases	11.1%, 5% (0.01%, 5%)	33.5%, 15% (10%, 15%)	20.2%, 10% (10%, 15%)
Texas	All	Accuracy	Deaths	9.13%, 5% (0%, 5%)	27.6%, 15% (10%, 15%)	16.9%, 10% (9.99%, 15%)
Texas	Respiratory season	Log score	Cases	59.4%, 0.34 (0.26, 0.42)	77.3%, 0.43 (0.36, 0.51)	11.3%, 0.05 (0.04, 0.07)
Texas	Respiratory season	Log score	Deaths	51.9%, 0.3 (0.23, 0.37)	68%, 0.42 (0.35, 0.49)	10.6%, 0.07 (0.05, 0.08)
Texas	Respiratory season	Accuracy	Cases	50.1%, 20% (15%, 25%)	96.9%, 30% (25%, 35%)	31.2%, 20% (15%, 25%)
Texas	Respiratory season	Accuracy	Deaths	47%, 25% (20%, 25%)	91.5%, 40% (35%, 40%)	30.2%, 25% (20%, 25%)
Texas	Off season	Log score	Cases	-38.5%, -0.22 (-0.27, -0.18)*	-29.9%, -0.13 (-0.17, -0.096)*	14%, 0.06 (0.05, 0.08)
Texas	Off season	Log score	Deaths	-16.3%, 0.02 (0.02, 0.02)*	-10.1%, 0.01 (0.01, 0.02)*	7.43%, -1.8e-06 (-0.00099, 0.00049)*

Texas	Off season	Accuracy	Cases	-16%, -10% (-15%, -5.01%)*	-10.5%, -5% (-10%, -5%)*	6.57%, 5% (0.01%, 5%)
Texas	Off season	Accuracy	Deaths	-18.8%, -15% (-15%, -10%)*	-19.6%, -15% (-15%, -10%)*	-0.909%, 0% (-0.01%, 0%)*
Washington	All	Log score	Cases	-14%, -0.092 (-0.11, -0.078)*	-13.5%, -0.098 (-0.11, -0.084)*	0.577%, 0.01 (0, 0.01)*
Washington	All	Log score	Deaths	-4.44%, -0.002 (-0.007, 0.00092)*	-1.65%, 0 (-0.0015, 0)*	2.92%, 0.01 (0.01, 0.01)*
Washington	All	Accuracy	Cases	16.5%, 5% (4.99%, 10%)	13.5%, 5% (0.01%, 10%)	-2.54%, 0% (0%, 0.01%)*
Washington	All	Accuracy	Deaths	11%, 5.01% (0%, 10%)	11.3%, 5.01% (5%, 9.99%)	0.291%, 0% (-0.01%, 0%)*
Washington	Respiratory season	Log score	Cases	0.837%, -0.026 (-0.046, -0.0079)*	3.75%, -0.0025 (-0.018, 0.01)*	2.89%, 0.03 (0.02, 0.03)*
Washington	Respiratory season	Log score	Deaths	0.291%, -0.05 (-0.068, -0.032)*	2.95%, -0.032 (-0.046, -0.017)*	2.65%, 0.02 (0.01, 0.02)*
Washington	Respiratory season	Accuracy	Cases	27%, 10% (5%, 15%)	25.6%, 10% (5.01%, 15%)	-1.03%, 0% (-0.01%, 0%)*
Washington	Respiratory season	Accuracy	Deaths	23.9%, 10% (10%, 15%)	29.2%, 15% (10%, 20%)	4.31%, 4.99% (0%, 5%)*
Washington	Off season	Log score	Cases	-22.7%, -0.15 (-0.17, -0.13)*	-23.4%, -0.19 (-0.22, -0.17)*	-0.949%, -0.01 (-0.018, -0.0035)*
Washington	Off season	Log score	Deaths	-7.49%, 0.01 (0.01, 0.01)*	-4.62%, 0.01 (0.01, 0.01)*	3.1%, 0 (0, 0)*
Washington	Off season	Accuracy	Cases	5.51%, 0.01% (0%, 5.01%)*	0.819%, 0.01% (0%, 5%)*	-4.45%, 0% (-5%, 0%)*
Washington	Off season	Accuracy	Deaths	-1.29%, -0.01% (-5%, 0%)*	-5.72%, -5% (-5%, 0%)*	-4.5%, -5% (-5%, 0%)*
Wyoming	All	Log score	Cases	0.44%, -0.00092 (-0.007, 0)*	1.31%, 0 (-0.0045, 0.01)*	0.869%, 0.01 (0.01, 0.01)*
Wyoming	All	Log score	Deaths	8.84%, 0.03 (0.02, 0.03)*	12.6%, 0.03 (0.02, 0.03)*	3.47%, 0 (0, 0.01)*
Wyoming	All	Accuracy	Cases	6.6%, 4.99% (0%, 5%)*	14.4%, 5% (5%, 10%)	7.28%, 5% (0.01%, 5.01%)
Wyoming	All	Accuracy	Deaths	3.37%, 0.01% (0%, 5%)*	7.98%, 5% (0%, 5%)	4.46%, 0% (-0.01%, 5%)*
Wyoming	Respiratory season	Log score	Cases	40.7%, 0.19 (0.16, 0.22)	42.9%, 0.17 (0.15, 0.2)	1.51%, -0.0036 (-0.013, 0)*
Wyoming	Respiratory season	Log score	Deaths	34.1%, 0.18 (0.14, 0.21)	39.6%, 0.16 (0.13, 0.19)	4.1%, 8.3e-05 (-0.0084, 0.01)*
Wyoming	Respiratory season	Accuracy	Cases	57.9%, 20% (15%, 25%)	70.8%, 25% (20%, 30%)	8.14%, 5% (0.01%, 10%)

Wyoming	Respiratory season	Accuracy	Deaths	29.6%, 15% (10%, 20%)	41.1%, 20% (15%, 25%)	8.87%, 5% (0%, 10%)
Wyoming	Off season	Log score	Cases	-19.5%, -0.15 (-0.18, -0.12)*	-19.1%, -0.13 (-0.16, -0.093)*	0.454%, 0.02 (0.01, 0.02)*
Wyoming	Off season	Log score	Deaths	-5.06%, 0.01 (0.01, 0.01)*	-2.16%, 0.01 (0.01, 0.02)*	3.05%, 0.01 (0, 0.01)*
Wyoming	Off season	Accuracy	Cases	-20%, -10% (-15%, -5%)*	-14.9%, -5% (-10%, 0%)*	6.39%, 5% (0%, 10%)
Wyoming	Off season	Accuracy	Deaths	-14.2%, -9.99% (-10%, -5.01%)*	-14.2%, -9.99% (-10%, -5%)*	0%, 0% (-0.01%, 5%)*

Table S5. Comparison of forecast performance of the ARIMAX models. Only four models (see the top row for model names) are shown here because the fifth model (ARIMAX.FULL with vaccination included) was only able to generate forecasts for less than half of the study weeks; see details on the models in the main text. Numbers show the mean log score or point prediction accuracy of forecasts (specified in the "metric" column), aggregated across the entire study period and all locations for all forecast targets combined or individual forecast targets (specified in the "target" column). Bolded fonts indicate best performance (highest log score or accuracy).

target	metric	measure	Models			
			ARIMA	ARIMAX.MOB	ARIMAX.SN	ARIMAX.MS
all	Log score	Cases	-2.64	**-2.53**	-2.75	-3.03
all	Log score	Deaths	-1.77	-1.73	**-1.64**	-1.71
all	Accuracy	Cases	13%	15%	**18%**	15%
all	Accuracy	Deaths	14%	17%	**21%**	17%
1-8wk ahead	Log score	Cases	-2.08	**-2**	-2.04	-2.08
1-8wk ahead	Log score	Deaths	-1.34	-1.36	**-1.27**	-1.34
1-8wk ahead	Accuracy	Cases	22%	25%	**26%**	24%
1-8wk ahead	Accuracy	Deaths	22%	25%	**28%**	23%
9-16wk ahead	Log score	Cases	-2.86	**-2.62**	-2.8	-3.14
9-16wk ahead	Log score	Deaths	-1.89	-1.8	**-1.64**	-1.68
9-16wk ahead	Accuracy	Cases	8%	11%	**14%**	11%
9-16wk ahead	Accuracy	Deaths	8%	12%	**18%**	12%
17-26wk ahead	Log score	Cases	-2.89	**-2.77**	-3.26	-3.77
17-26wk ahead	Log score	Deaths	-1.82	-1.75	**-1.72**	-1.76
17-26wk ahead	Accuracy	Cases	8%	10%	**12%**	10%
17-26wk ahead	Accuracy	Deaths	10%	12%	**16%**	12%
peak intensity	Log score	Cases	**-3.87**	-4.45	-4.39	-4.57
peak intensity	Log score	Deaths	**-3.14**	-3.38	-3.18	-3.5
peak intensity	Accuracy	Cases	14%	15%	**19%**	18%
peak intensity	Accuracy	Deaths	15%	18%	**23%**	21%
peak week	Log score	Cases	**-2.63**	-2.66	-3.01	-3.21
peak week	Log score	Deaths	-2.54	-2.53	**-2.36**	-2.45
peak week	Accuracy	Cases	11%	12%	**20%**	21%
peak week	Accuracy	Deaths	11%	13%	**23%**	23%
total	Log score	Cases	-2.37	**-2.36**	-2.54	-2.5
total	Log score	Deaths	**-2.22**	-2.27	-2.29	-2.56
total	Accuracy	Cases	10%	12%	**13%**	**13%**
total	Accuracy	Deaths	12%	13%	17%	**19%**

Table S6. Comparison of forecast performance of the approaches developed in this study with the best-performing ARIMAX model. Numbers show the mean log score or point prediction accuracy of forecasts (specified in the "metric" column), aggregated across the entire study period and all locations for all forecast targets combined or individual forecast targets (specified in the "target" column). Bolded fonts indicate best performance (highest log score or accuracy).

target	measure	Log score			Accuracy		
		ARIMAX.SN	Baseline	Best-performing	ARIMAX.SN	Baseline	Best-performing
all	Cases	-2.75	-1.95	**-1.46**	18%	11%	**26%**
all	Deaths	-1.64	-0.97	**-0.65**	21%	17%	**31%**
1-8wk ahead	Cases	-2.04	-1.08	**-0.91**	26%	26%	**38%**
1-8wk ahead	Deaths	-1.27	-0.42	**-0.35**	28%	39%	**48%**
9-16wk ahead	Cases	-2.8	-1.86	**-1.49**	14%	4%	**20%**
9-16wk ahead	Deaths	-1.64	-0.83	**-0.64**	18%	7%	**25%**
17-26wk ahead	Cases	-3.26	-2.8	**-1.87**	12%	1%	**16%**
17-26wk ahead	Deaths	-1.72	-1.43	**-0.8**	**16%**	1%	**16%**
peak intensity	Cases	-4.39	-2.43	**-2.01**	19%	20%	**40%**
peak intensity	Deaths	-3.18	-1.69	**-1.36**	23%	30%	**51%**
peak week	Cases	-3.01	-3.51	**-2.73**	20%	24%	**42%**
peak week	Deaths	-2.36	-2.61	**-1.53**	23%	35%	**56%**
total	Cases	-2.54	-1.05	**-0.75**	13%	7%	**33%**
total	Deaths	-2.29	-0.99	**-0.67**	17%	9%	**36%**

Table S7. Preliminary assessment of the real-time forecasts initiated the week of October 2, 2022 for October 2022 – March 2023. The log score and accuracy were computed using reported case and mortality data downloaded on March 31, 2023 (see further details in the main text). As shown in Fig 8, COVID-19 mortality data in some states (e.g., Wyoming) were highly irregular during the forecast period, likely an artifact of reporting. Due to these potential data inaccuracies, the mortality-related log score and point prediction accuracy for these states are likely lower than the true values (to be obtained once more complete mortality data are available).

State	target	Log score Cases	Log score Deaths	Accuracy Cases	Accuracy Deaths
All	all	-0.45	-0.2	56%	23%
All	1-8wk ahead	-0.31	-0.06	56%	22%
All	9-16wk ahead	-0.71	-0.17	46%	20%
All	17-26wk ahead	-0.25	-0.12	64%	28%
All	peak intensity	-0.84	-0.32	48%	6%
All	peak week	-1.21	-2.3	52%	41%
All	total	-0.21	-0.13	78%	7%
California	all	-0.52	-0.1	60%	52%
California	1-8wk ahead	-0.31	-0.04	55%	32%
California	9-16wk ahead	-0.99	-0.11	41%	74%
California	17-26wk ahead	-0.24	-0.06	73%	43%
California	peak intensity	-1.39	-0.1	90%	60%
California	peak week	-0.72	-0.86	100%	100%
California	total	-0.24	-0.1	60%	60%
Florida	all	-0.38	-0.19	28%	8%
Florida	1-8wk ahead	-0.06	-0.02	5%	0%
Florida	9-16wk ahead	-0.66	-0.2	9%	14%
Florida	17-26wk ahead	-0.31	-0.16	56%	13%
Florida	peak intensity	-1.2	-0.54	0%	0%
Florida	peak week	-0.74	-1.6	90%	0%
Florida	total	-0.16	-0.05	50%	0%
Iowa	all	-0.37	-0.12	53%	29%
Iowa	1-8wk ahead	-0.2	-0.05	86%	12%
Iowa	9-16wk ahead	-0.59	-0.09	42%	24%
Iowa	17-26wk ahead	-0.2	-0.07	29%	49%
Iowa	peak intensity	-0.71	-0.11	80%	0%
Iowa	peak week	-1.37	-1.38	60%	70%
Iowa	total	-0.26	-0.05	70%	0%
Massachusetts	all	-0.64	-0.31	61%	9%
Massachusetts	1-8wk ahead	-0.7	-0.06	41%	18%
Massachusetts	9-16wk ahead	-0.86	-0.46	72%	6%

Massachusetts	17-26wk ahead	-0.36	-0.2	78%	0%
Massachusetts	peak intensity	-1.33	-0.61	0%	0%
Massachusetts	peak week	-0.95	-1.62	0%	70%
Massachusetts	total	-0.26	-0.7	80%	0%
Michigan	all	-0.32	-0.32	51%	17%
Michigan	1-8wk ahead	-0.3	-0.2	45%	25%
Michigan	9-16wk ahead	-0.46	-0.21	64%	12%
Michigan	17-26wk ahead	-0.11	-0.22	41%	19%
Michigan	peak intensity	-0.35	-0.12	100%	0%
Michigan	peak week	-1.81	-3.59	0%	0%
Michigan	total	-0.06	-0.05	90%	0%
New York	all	-0.76	-0.14	66%	17%
New York	1-8wk ahead	-0.68	-0.07	52%	14%
New York	9-16wk ahead	-1.27	-0.05	48%	0%
New York	17-26wk ahead	-0.34	-0.05	98%	37%
New York	peak intensity	-0.97	-0.11	30%	0%
New York	peak week	-1.76	-2.31	10%	0%
New York	total	-0.24	-0.06	90%	0%
Pennsylvania	all	-0.49	-0.12	59%	37%
Pennsylvania	1-8wk ahead	-0.33	-0.05	81%	25%
Pennsylvania	9-16wk ahead	-0.75	-0.1	34%	30%
Pennsylvania	17-26wk ahead	-0.34	-0.08	62%	53%
Pennsylvania	peak intensity	-0.73	-0.16	0%	0%
Pennsylvania	peak week	-1.09	-1.33	100%	90%
Pennsylvania	total	-0.21	-0.08	80%	0%
Texas	all	-0.37	-0.08	64%	10%
Texas	1-8wk ahead	-0.22	-0.03	78%	4%
Texas	9-16wk ahead	-0.67	-0.05	60%	19%
Texas	17-26wk ahead	-0.18	-0.04	50%	3%
Texas	peak intensity	-0.75	-0.09	70%	0%
Texas	peak week	-0.83	-1.22	100%	70%
Texas	total	-0.26	-0.05	80%	0%
Washington	all	-0.26	-0.3	78%	31%
Washington	1-8wk ahead	-0.21	-0.04	75%	65%
Washington	9-16wk ahead	-0.35	-0.1	62%	12%
Washington	17-26wk ahead	-0.15	-0.07	92%	26%
Washington	peak intensity	-0.52	-0.08	90%	0%
Washington	peak week	-0.76	-6.85	60%	0%
Washington	total	-0.22	-0.06	90%	10%
Wyoming	all	-0.35	-0.29	44%	21%

Wyoming	1-8wk ahead	-0.14	-0.03	40%	25%
Wyoming	9-16wk ahead	-0.47	-0.3	29%	9%
Wyoming	17-26wk ahead	-0.27	-0.21	63%	33%
Wyoming	peak intensity	-0.42	-1.29	20%	0%
Wyoming	peak week	-2.1	-2.23	0%	10%
Wyoming	total	-0.21	-0.04	90%	0%

Table S8. Prior ranges for the parameters and variables used in the model-inference system. Parameters/state variables are initialized by drawing from uniform distributions specified in the rows labeled "Initialization". During the filtering process, space-reprobing is applied to explore the state space, i.e., a small fraction of the ensemble members are randomly replaced with values drawn from the uniform distributions specified in the rows labeled with "Space-reprobing".

Type	Parameters/ variables	Symbol	Range	Note
Initialization	Initial susceptible	S(t=0)	All locations: non-Omicron period, U[99%, 100%] population; Omicron period, U[50%, 90%] population	n/a
Initialization	Initial exposed	E(t=0)	All locations: U[5, 50] × no. cases during 1st week	n/a
Initialization	Initial infectious	I(t=0)	All locations: U[5,50] × no. cases during 1st week	n/a
Initialization	Infectious period	D	All locations: U[2, 5] days	n/a
Initialization	Latency period	Z	All locations: U[2, 5] days	n/a
Initialization	Duration of immunity (from prior infection)	L	All locations: non-Omicron period, U[2, 3] years; Omicron period: U[1, 3] years	n/a
Initialization	Time-to-detection, mean	Td, mean	All locations: U[5, 8] days	n/a
Initialization	Time-to-detection, sd	Td, sd	All locations: U[1, 3] days	To allow variation in time to diagnosis/reporting
Initialization	Scaling of NPI effectiveness	e	All locations: U[0.5, 1.5]	Around 1, with a large bound to be flexible
Initialization	Vaccine efficacy (VE)	n/a	All locations: before Delta, VE1=85%, VE2 = 95%; Delta, VE1 = 50%, VE2 = 80%; Omicron, VE1 = 10%, VE2 (combined 2nd and 3rd doses) = 70%	Used higher VE values, as the observations included both cases/infections and

				deaths; i.e., here VE is for both infections and mortality
Initialization	VE waning	ρ	rho(t) = 1/(1+exp(-k * (t - tm.imm/2)); for wildtype: k = 0.026; tm.imm = 322; for Delta: k = 0.025; tm.imm = 280; for Omicron: k = 0.024; tm.imm = 256	Parameter in the logistic function fitted based on data from UKHSA
Initialization	Infection-detection rate	r	all locations: U [0.01, 0.05]	n/a
Initialization	Infection-fatality risk	IFR	all locations: U [0.005, 0.015]	n/a
Initialization	Transmission rate	β	Wyoming: U [0.41, 0.6]; Iowa, Texas, Washington: U [0.44, 0.75]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania: U [0.45, 0.75]	n/a
Space-reprobing	Transmission rate	β	Alpha (2021-02-14 to 2021-06-19): Wyoming, U [0.54, 0.9]; Iowa, Texas, Washington, U [0.57, 1.12]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.585, 1.125]; Delta (2021-06-06 to 2021-12-18): Wyoming, U [0.5, 1.02]; Iowa, Texas, U [0.52, 1.27]; Washington, U [0.53, 1.27]; California, Florida, Michigan, New York, Pennsylvania, U [0.54, 1.275]; Delta_holiday (2021-07-04 to 2021-07-31): Massachusetts, U [0.855, 1.275]; Delta1 (2021-06-13 to 2021-07-03): Massachusetts, U [0.54, 1.275]; Delta2 (2021-08-01 to 2021-08-21): Massachusetts, U [0.54, 1.02]; Delta3 (2021-08-22 to 2021-12-18): Massachusetts, U [0.54, 1.275]; Omicron_BA.1 (2021-12-05 to 2022-03-26): Wyoming, U [0.62, 1.2]; Texas, U [0.65, 1.5]; Iowa, Washington, U [0.66, 1.5]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.675, 1.5]; Omicron_BA.2 (2022-03-06 to 2022-05-07): Wyoming, U [0.75, 1.68]; Iowa, Texas, Washington, U [0.79, 2.1]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.81, 2.1]; Omicron_BA.2.12.1 (2022-04-03 to 2022-06-18): Wyoming, U [0.75, 1.68]; Iowa, Texas, Washington, U [0.79, 2.1]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.81, 2.1];	n/a

Space-reprobing	Infection-detection rate	r	Omicron_nonBA.1o2 (2022-06-05 to 2022-12-31): Wyoming, U [0.75, 1.68]; Iowa, Texas, Washington, U [0.79, 2.1]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.81, 2.1]; wave1 (2020-01-01 to 2020-09-30): Wyoming, U [0.41, 0.6]; Iowa, Texas, Washington, U [0.44, 0.75]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.45, 0.75]; wave2 (2020-10-01 to 2021-03-20): Wyoming, U [0.41, 0.66]; Iowa, Texas, Washington, U [0.44, 0.83]; California, Florida, Massachusetts, Michigan, New York, Pennsylvania, U [0.45, 0.825] 2020summer (2020-06-01 to 2020-10-03): Massachusetts, New York, Wyoming, U [0.05, 0.25]; Michigan, Pennsylvania, U [0.05, 0.3125]; California, Florida, Iowa, Texas, Washington, U [0.05, 0.375]; 2021summer (2021-06-01 to 2021-06-30): California, Iowa, Massachusetts, Michigan, New York, Pennsylvania, U [0.02, 0.1]; California, Florida, Iowa, Massachusetts, Michigan, New York, Pennsylvania, Texas, Washington, U [0.03, 0.25]; Alpha (2021-02-14 to 2021-05-31): Florida, Iowa, Massachusetts, Michigan, Pennsylvania, Texas, U [0.2, 0.4]; California, New York, Washington, Wyoming, U [0.2, 0.48]; Delta (2021-05-31 to 2022-01-01): Florida, Texas, Washington, Wyoming, U [0.1, 0.5]; Delta1 (2021-06-21 to 2021-07-17): California, Iowa, Massachusetts, Michigan, New York, Pennsylvania, U [0.1, 0.5]; Delta2 (2021-06-27 to 2021-08-08): California, Iowa, Massachusetts, Michigan, New York, Pennsylvania, U [0.3, 0.5]; Delta3 (2021-07-19 to 2022-01-08): California, Iowa, Massachusetts, Michigan, New York, Pennsylvania, U [0.1, 0.5]; massvax (2021-05-14 to 2021-05-31): California, Iowa, Massachusetts, Michigan, New York, Pennsylvania, Washington, U [0.05, 0.3]; Omicron0 (2021-10-15 to 2021-12-11): all locations, U [0.001, 0.05]; Omicron1a (2021-12-05 to 2021-12-18): all locations, U [0.1, 0.5]; Omicron1b (2021-12-05 to 2021-12-25): all locations, U [0.1, 0.6]; Omicron2 (2021-12-26 to 2022-06-18): all locations, U [0.05, 0.2]; Omicron3 (2022-06-05 to 2022-12-31): all locations, U [0.02, 0.18]; wave1 (2020-03-08 to 2020-05-31): all locations, U [0.08, 0.35]; wave2 (2020-09-06 to 2021-03-20): Florida, Iowa, Massachusetts, Michigan,	n/a

			Pennsylvania, Texas, U [0.12, 0.4]; New York, Washington, Wyoming, U [0.144, 0.48]; California, U [0.144, 0.54]	
Space-reprobing	Infection-fatality risk	IFR	2020summer (2020-06-01 to 2020-09-30): all locations, U [1e-04, 0.005]; Alpha (2021-03-07 to 2021-06-19): all locations, U [1e-04, 0.015]; Delta (2021-06-13 to 2022-01-01): all locations, U [1e-04, 0.015]; massvax (2021-05-14 to 2021-06-26): California, Florida, Iowa, Massachusetts, Michigan, New York, Pennsylvania, Texas, Washington, U [1e-04, 0.01]; Omicron_BA.1 (2021-12-12 to 2022-06-18): all locations, U [4e-05, 0.004]; Omicron_nonBA.1 (2022-06-05 to 2022-12-31): all locations, U [8e-06, 0.0032]; wave1early (2020-03-16 to 2020-04-15): all locations, U [0.005, 0.025]; wave1late (2020-04-16 to 2020-05-31): all locations, U [0.001, 0.015]; wave2 (2020-10-01 to 2021-04-24): all locations, U [2e-04, 0.0125]	n/a